var title_f19_6_19552="Lateral viewing telescope";
var content_f19_6_19552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral viewing telescope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic drawing of a lateral viewing telescope inserted through a rigid bronchoscope for the purpose of examining the right upper lobe bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19552=[""].join("\n");
var outline_f19_6_19552=null;
var title_f19_6_19553="Melioidosis prostatic abscess";
var content_f19_6_19553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography of prostatic abscess due to melioidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large prostatic abscess in a case of melioidosis seen on CT scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19553=[""].join("\n");
var outline_f19_6_19553=null;
var title_f19_6_19554="Amount of topical medications";
var content_f19_6_19554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76586%7EDERM%2F62402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76586%7EDERM%2F62402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amount of topical medication for adult use",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        BID/1 week",
"       </td>",
"       <td class=\"subtitle1\">",
"        TID/2 week",
"       </td>",
"       <td class=\"subtitle1\">",
"        BID/4 week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Face and neck",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trunk",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"       <td>",
"        180 g",
"       </td>",
"       <td>",
"        240 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One arm",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One leg",
"       </td>",
"       <td>",
"        30 g",
"       </td>",
"       <td>",
"        90 g",
"       </td>",
"       <td>",
"        120 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hands and feet",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body",
"       </td>",
"       <td>",
"        180 g",
"       </td>",
"       <td>",
"        0.75 to 1 kg",
"       </td>",
"       <td>",
"        1.25 to 2 kg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For children use one-third to one-half these amounts.",
"    <div class=\"footnotes\">",
"     BID: two times per day; TID: three times per day.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldstein BG, Goldstein AO, Practical Dermatology 2nd ed, Mosby-Year Book, Inc, St. Louis, MO, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of representative topical corticosteroid preparations (classified according to the USA system)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Potency group*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Corticosteroid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vehicle type/form",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade names",
"        <br/>",
"        (US)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Available strength(s), percent",
"        <br/>",
"        (except as noted)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic available in US",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"18\">",
"        <strong>",
"         Super high potency",
"         <br/>",
"         (group one)",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Betamethasone dipropionate, augmented",
"       </td>",
"       <td>",
"        Ointment, optimized",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Clobetasol propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, emollient base",
"       </td>",
"       <td>",
"        Temovate E&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam aerosol",
"       </td>",
"       <td>",
"        Olux-E&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam aerosol (scalp)",
"       </td>",
"       <td>",
"        Olux&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shampoo",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution (scalp)",
"       </td>",
"       <td>",
"        Temovate&reg;, Cormax&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spray aerosol",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Halobetasol propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Ultravate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Ultravate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Vanos&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Tape (roll)",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        4 mcg/cm",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Ointment (petrolatum)",
"       </td>",
"       <td>",
"        Psorcon&reg;, ApexiCon&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        <strong>",
"         High potency",
"         <br/>",
"         (group two)",
"        </strong>",
"       </td>",
"       <td>",
"        Amcinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cyclocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, augmented formulation (AF)",
"       </td>",
"       <td>",
"        Diprolene&reg; AF",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Halcinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Halog&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Halog&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream anhydrous",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Ointment, emollient",
"       </td>",
"       <td>",
"        ApexiCon&reg;, Florone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, emollient",
"       </td>",
"       <td>",
"        ApexiCon&reg; E",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Desoximetasone",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"14\">",
"        <strong>",
"         High potency",
"         <br/>",
"         (group three)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Amcinonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cyclocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Cream, hydrophilic emollient",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        Luxiq&reg;",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluticasone propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Cream aqueous emollient",
"       </td>",
"       <td>",
"        Lidex-E&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mometasone furoate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desoximetasone",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Topicort LP&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Florone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog &reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Triderm&reg;, Aristocort HP&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Aristocort A&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"10\">",
"        <strong>",
"         Medium potency",
"         <br/>",
"         (group four)",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosol spray",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"       </td>",
"       <td>",
"        0.2 mg per 2 second spray",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Mometasone furoate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Elocon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone valerate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Westcort&reg;",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clocortolone pivalate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cloderm&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"20\">",
"        <strong>",
"         Lower-mid potency",
"         <br/>",
"         (group five)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fluticasone propionate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Prednicarbate",
"       </td>",
"       <td>",
"        Cream, emollient",
"       </td>",
"       <td>",
"        Dermatop&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Dermatop&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Desonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        DesOwen&reg;, Tridesilon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Desonate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Beta-Val&reg;, Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone valerate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Westcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Hydrocortisone butyrate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Locoid&reg;, Locoid Lipocream&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion, spray",
"       </td>",
"       <td>",
"        Cortizone10&reg; maximum",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone probutate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Pandel&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"13\">",
"        <strong>",
"         Low potency",
"         <br/>",
"         (group six)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Alclometasone dipropionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Aclovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Aclovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Aristocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Desonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        DesOwen&reg; , Tridesilon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        DesOwen&reg;, LoKara&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        Verdeso&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Beta-Val&reg;, Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shampoo",
"       </td>",
"       <td>",
"        Capex&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oil (scalp)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Derma-Smoothe/FS&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oil (body)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Derma-Smoothe/FS&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        <strong>",
"         Least potent",
"         <br/>",
"         (group seven)",
"        </strong>",
"       </td>",
"       <td rowspan=\"4\">",
"        Hydrocortisone (base)",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Hytone&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Hytone&reg;, Nutracort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Hytone&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Texacort&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Hydrocortisone acetate with pramoxine 1 percent combination",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Pramosone&reg;",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Pramosone&reg;, Analpram HC",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Pramosone&reg;, Analpram HC",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosol foam",
"       </td>",
"       <td>",
"        Epifoam&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Hydrocortisone (base)",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cortaid&reg;, Hytone&reg;, Nutracort&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cortaid&reg;, Hytone&reg;, Synacort",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Aquinil HC&reg;, Sarnol HC&reg;, Cortizone-10&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spray",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Cortaid&reg;, Noble&reg;, Scalp relief&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Listed by potency according to the USA classification system: group one is the most potent, group seven is the least potent. Other countries use a different classification system with only four or five groups.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Vehicle and base ingredient(s) for generic products, in some cases, may not be identical to trade version.",
"      <br>",
"       &Delta; Inactive US trade name for specific product; brand may be available outside US.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved; and Tadicherla S, Ross K, Shenefelt D, Topical corticosteroids in dermatology; Journal of Drugs in Dermatology 2009; 12:1093.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19554=[""].join("\n");
var outline_f19_6_19554=null;
var title_f19_6_19555="Sunburn blistering";
var content_f19_6_19555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sunburn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema, edema, and bullae are present on this child with a severe sunburn.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19555=[""].join("\n");
var outline_f19_6_19555=null;
var title_f19_6_19556="Urea: Patient drug information";
var content_f19_6_19556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Urea: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/3/22582?source=see_link\">",
"     see \"Urea: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aluvea&trade;;",
"     </li>",
"     <li>",
"      Aqua Care&reg; [OTC];",
"     </li>",
"     <li>",
"      Aquaphilic&reg; with Carbamide [OTC];",
"     </li>",
"     <li>",
"      BP 50%;",
"     </li>",
"     <li>",
"      Carmol&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Carmol&reg; 20 [OTC];",
"     </li>",
"     <li>",
"      Carmol&reg; 40;",
"     </li>",
"     <li>",
"      Carmol&reg; Deep Cleansing [OTC];",
"     </li>",
"     <li>",
"      DPM&trade; [OTC];",
"     </li>",
"     <li>",
"      Gordon's&reg; Urea [OTC];",
"     </li>",
"     <li>",
"      Gormel&reg; Ten [OTC];",
"     </li>",
"     <li>",
"      Gormel&reg; [OTC];",
"     </li>",
"     <li>",
"      Hydro 35&trade;;",
"     </li>",
"     <li>",
"      Hydro 40&trade;;",
"     </li>",
"     <li>",
"      Kerafoam&reg;;",
"     </li>",
"     <li>",
"      Kerafoam&reg; 42;",
"     </li>",
"     <li>",
"      Keralac&trade;;",
"     </li>",
"     <li>",
"      Keralac&trade; Nailstik;",
"     </li>",
"     <li>",
"      Kerol&trade;;",
"     </li>",
"     <li>",
"      Kerol&trade; AD;",
"     </li>",
"     <li>",
"      Kerol&trade; Redi-Cloths;",
"     </li>",
"     <li>",
"      Kerol&trade; ZX;",
"     </li>",
"     <li>",
"      Lanaphilic&reg; with Urea [OTC];",
"     </li>",
"     <li>",
"      Nutraplus&reg; [OTC];",
"     </li>",
"     <li>",
"      Quinnostik;",
"     </li>",
"     <li>",
"      Rea Lo&reg; 30 [OTC];",
"     </li>",
"     <li>",
"      Rea Lo&reg; 40;",
"     </li>",
"     <li>",
"      Remeven&trade;;",
"     </li>",
"     <li>",
"      RevitaDERM&reg; 40;",
"     </li>",
"     <li>",
"      Ultra Mide 25&reg; [OTC];",
"     </li>",
"     <li>",
"      Umecta PD&trade;;",
"     </li>",
"     <li>",
"      Umecta&reg;;",
"     </li>",
"     <li>",
"      Umecta&reg; Nail Film;",
"     </li>",
"     <li>",
"      Uramaxin&reg;;",
"     </li>",
"     <li>",
"      Uramaxin&reg; GT;",
"     </li>",
"     <li>",
"      Uramaxin&reg; GT Kit;",
"     </li>",
"     <li>",
"      Ureacin-10&reg; [OTC];",
"     </li>",
"     <li>",
"      Ureacin-20&reg; [OTC];",
"     </li>",
"     <li>",
"      X-Viate&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      UltraMide 25&trade;;",
"     </li>",
"     <li>",
"      Uremol&reg;;",
"     </li>",
"     <li>",
"      Urisec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to moisturize skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some nail problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691784",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cervicitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to urea or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet hair before shampoo.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Work into hair gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse fully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use cream vaginally.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11898 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19556=[""].join("\n");
var outline_f19_6_19556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232453\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232454\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012396\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012395\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012400\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012401\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012403\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012398\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012399\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012404\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012405\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/3/22582?source=related_link\">",
"      Urea: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_6_19557="Histol microinvasive melanoma";
var content_f19_6_19557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microinvasive radial growth phase melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light photomicrograph of a microinvasive radial growth phase superficial spreading melanoma. In addition to epidermal involvement, this superficial spreading melanoma is characterized by dermal extension of the tumor cells (white arrow). However, the largest dermal nest is not larger than the largest epidermal nest, and there are no dermal mitoses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19557=[""].join("\n");
var outline_f19_6_19557=null;
var title_f19_6_19558="Invasive hemodynamic tracing LV and aortic pressures HCM";
var content_f19_6_19558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Invasive hemodynamic tracing obtained during cardiac catheterization showing left ventricular (LV) and aortic pressures in a patient with obstructive hypertrophic cardiomyopathy (HCM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous left ventricular (LV) and aortic (Ao) pressures in a patient with obstructive hypertrophic cardiomyopathy show a significant gradient and the LV pressure is higher than that in the Ao. The Ao pressure waveform has a rapid upstroke and there is a spike and dome configuration. As the LV catheter is pulled back (arrow) to a LV position just below the aortic valve, the gradient is obliterated and the Ao and LV pressures become equal, indicating a transventricular and not a transvalvular gradient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Kern MJ (ed). Cardiac Catheterization Handbook, 2nd ed. Mosby-Year Book, St. Louis, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19558=[""].join("\n");
var outline_f19_6_19558=null;
var title_f19_6_19559="Diagnostic assays for toxoplasmosis infection";
var content_f19_6_19559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic assays for toxoplasmosis infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19559/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19559/contributors\">",
"     Joseph D Schwartzman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19559/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19559/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19559/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/6/19559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13029269\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis is a worldwide zoonosis caused by the intracellular protozoan parasite, Toxoplasma gondii (T. gondii). Infection in humans most commonly occurs through the ingestion of raw or undercooked meat that contains tissue cysts, through ingestion of water or food contaminated with oocysts, or congenitally through transplacental transmission from a mother who acquired infection during pregnancy.",
"   </p>",
"   <p>",
"    Laboratory testing is usually necessary to establish the diagnosis of toxoplasmosis, because the clinical manifestations of infection are so protean. The diagnostic methodology is complex and requires careful consideration based on the patient&rsquo;s clinical presentation.",
"   </p>",
"   <p>",
"    This topic will address diagnostic techniques for toxoplasmosis in the immunocompetent and immunocompromised adult and will give guidance as to which approach should be used in various clinical scenarios. Toxoplasmosis in the pregnant female, newborn, or in the patient with ocular disease is discussed elsewhere. The epidemiology, clinical manifestations, and treatment of toxoplasmosis are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=see_link\">",
"     \"Congenital toxoplasmosis: Treatment, outcome, and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237188\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"   </p>",
"   <p>",
"    The clinical presentation of toxoplasmosis varies depending on the host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237203\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of adults with primary toxoplasma infection are asymptomatic. When symptoms do occur, patients often complain of fevers, chills, and sweats in association with prominent cervical lymphadenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237210\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis persists as a latent infection for the lifetime of the host. Reactivation of toxoplasmosis can occur at any time the host becomes immunocompromised or immunosuppressed. Reactivation disease in the immunocompromised host usually occurs within the central nervous system as multiple brain abscesses. Patients may present with headache or focal neurologic signs or symptoms, such as hemiplegia. Other causes of enhancing mass lesions include lymphoma, metastatic carcinoma, bacterial abscesses, or tuberculomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237275\">",
"    <span class=\"h1\">",
"     AVAILABLE DIAGNOSTIC MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available diagnostic modalities for T. gondii include molecular-based techniques, such as polymerase chain reaction (PCR) based assays, histopathology, and serologic assays, which are the cornerstone for the initial step in diagnosis or acute or reactivation disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237544\">",
"    <span class=\"h2\">",
"     Serologic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. gondii infection can be diagnosed indirectly with serologic testing in the appropriate clinical context. Various serologic assays measure different types of toxoplasma-specific antibodies, such as IgM or IgG fractions. However, there is no single serologic test that can be used to support the diagnosis of acute or chronic infection by T. gondii. In most cases, a panel of tests is required to distinguish between acute and chronic infection, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Sabin-Feldman dye test, immunofluorescence antibody (IFA) test, enzyme-linked immunosorbent assay (ELISA), IgG avidity test, and agglutination assays can all be used for detection of IgG antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/2\">",
"     2",
"    </a>",
"    ]. Some of these tests are available commercially, while others are only available in specialized research laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/1,3-13\">",
"     1,3-13",
"    </a>",
"    ]. The Sabin-Feldman test was the reference gold standard for testing blood or cerebral spinal fluid (CSF) since 1948, but is now only available in certain reference laboratories, such as the Palo Alto Foundation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. Several commercial ELISA tests are available for testing toxoplasma-specific IgM and IgG antibody, although the performance of these tests varies. For example, one study of six different IgG ELISA test kits, conducted by the Food and Drug Administration (FDA), demonstrated that the sensitivity ranged from 93 to 100 percent and the specificity ranged from 78 to 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/15\">",
"     15",
"    </a>",
"    ]. Other tests that measure toxoplasma-specific IgM antibodies include the IFA and the agglutination assay [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10842706\">",
"    <span class=\"h3\">",
"     Patterns of antibody responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute infection, IgM antibodies usually appear within one week and continue to rise. The IgM titer subsequently declines and disappears, but the rate of decline is highly variable from individual to individual [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/2\">",
"     2",
"    </a>",
"    ]. Toxoplasma-specific IgG antibodies subsequently follow within approximately two weeks of primary infection, peak within approximately eight weeks, and generally persist for life. There is no direct correlation between the height of the IgG titer and the proximity of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10843435\">",
"    <span class=\"h3\">",
"     Interpretation of antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with symptoms and signs of primary toxoplasmosis, a reactive toxoplasma-specific IgM antibody paired with a non-reactive IgG antibody would be highly suggestive of acute infection. Diagnostic certainty would rise if repeat testing demonstrated appearance of toxoplasma-specific IgG antibody. In contrast, if the IgM antibody is positive two to three weeks later, but the IgG antibody remains negative, the clinician should suspect a false positive IgM result. Acute toxoplasmosis is highly unlikely in a patient with signs of cervical lymphadenopathy who has a negative toxoplasma-specific IgM antibody.",
"   </p>",
"   <p>",
"    In clinical practice, it is more common to see a positive result for both IgM and IgG antibodies since the IgG antibody rises quickly after primary infection. Although this pattern could be related to acute toxoplasmosis, clinicians should be aware that IgM antibodies can persist for months (or years) after primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, a reactive IgM antibody test for toxoplasmosis must always be interpreted within the clinical context. If there is clinical suspicion of acute toxoplasmosis, diagnostic confirmation should be pursued with an alternative method of diagnostic testing, such as avidity testing. (See",
"    <a class=\"local\" href=\"#H3870347\">",
"     'When to order additional testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In an immunocompromised host with multiple brain abscesses, the presence of Toxoplasma-specific IgG antibody would be supportive of possible reactivation disease, while the absence of IgG would be strongly suggestive of an alternative diagnosis; toxoplasma-specific IgG antibodies usually remain positive for life, even in patients with AIDS. (See",
"    <a class=\"local\" href=\"#H5237257\">",
"     'Reactivation of infection in the immunocompromised host'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3870385\">",
"    <span class=\"h3\">",
"     False negative serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;False negative serologic testing may rarely occur in patients who have a primary immunodeficiency such as hypogammaglobulinemia, or among those who are significantly immunocompromised (eg, transplant patients or those with HIV infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3870392\">",
"    <span class=\"h3\">",
"     False positive serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive IgM antibody results are a significant issue in serologic testing for toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/16\">",
"     16",
"    </a>",
"    ]. A false positive IgM test result may be related to rheumatoid factor, antinuclear antibodies, and non-specific binding in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/16\">",
"     16",
"    </a>",
"    ]. As noted above, the decline of toxoplasma-specific IgM titers after acute infection is highly variable and may take months or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3870347\">",
"    <span class=\"h2\">",
"     When to order additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional testing should be performed for confirmation of acute infection in patients with a positive IgM serology for toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/2\">",
"     2",
"    </a>",
"    ]. Confirmatory assays that are sensitive and specific for Toxoplasma-specific IgM antibodies include the IgM capture ELISA. Alternatively, avidity testing or differential agglutination testing can help discriminate recently-acquired IgG antibodies from antibodies formed in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/8-13,17\">",
"     8-13,17",
"    </a>",
"    ]. Some reference laboratories, such as the Palo Alto Medical Foundation, offer advice to physicians regarding specimen handling and choice of testing at",
"    <a class=\"external\" href=\"file://www.pamf.org/serology/clinicianguide.html\">",
"     file://www.pamf.org/serology/clinicianguide.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87166188\">",
"    <span class=\"h3\">",
"     Avidity testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of IgG antibody &ldquo;avidity patterns&rdquo; help to determine whether an infection is acute or chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/18\">",
"     18",
"    </a>",
"    ]. Avidity testing, which is available commercially in the United States and Europe, is used as supplemental testing when confirmatory testing is desired (eg, a patient with serologic evidence of possible acute toxoplasma infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibody avidity to a specific antigen is lower in patients with recent infection than prior infection. Avidity is measured by exposing an antigen-antibody complex to reagents that can lead to dissociation of the specific toxoplasma IgG antibody from its antigen. Thus, the dissociation test can distinguish low avidity antibody (that seen with recently acquired infection) from high avidity antibody (that seen during infection that is more than four months old) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/13,20,21\">",
"     13,20,21",
"    </a>",
"    ]. As an example, acute toxoplasmosis would be unlikely in an immunocompetent host with cervical lymphadenopathy and a high avidity test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238977\">",
"    <span class=\"h3\">",
"     Agglutination assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agglutination tests (eg, immunosorbent agglutination assays; ISAGA) measure IgM and IgG antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/22\">",
"     22",
"    </a>",
"    ] and are available only at specific toxoplasma reference labs, such as the Palo Alto Foundation (",
"    <a class=\"external\" href=\"file://www.pamf.org/serology/clinicianguide.html\">",
"     file://www.pamf.org/serology/clinicianguide.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Various antibodies to T. gondii react differently when two different fixatives (eg, acetone and formalin) are used to fix the parasites. These properties have been used to differentiate antibodies that are formed either acutely or later in infection. For example, early antibodies react to acetone-fixed parasites, while antibodies that develop later in infection react to formalin-fixed parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10843290\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available polymerase chain reaction (PCR) assays can detect parasite DNA in blood, cerebral spinal fluid (CSF), aqueous humor, and fluid from bronchoalveolar lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Since there is no standardized PCR assay, the sensitivity of this assay varies widely (from 15 to 85 percent for blood), although specificity appears to be high (greater than 95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/27\">",
"     27",
"    </a>",
"    ]. In an immunocompromised host with suspected disseminated disease, PCR testing can be a helpful aid in diagnosis, although PCR is rarely performed in immunocompetent patients presenting with cervical lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237302\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma may be detected on histopathology in one of two forms: tachyzoites or cysts. Tachyzoites are crescent-shaped and usually establish the diagnosis of acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/3\">",
"     3",
"    </a>",
"    ]. Cysts are circular in shape and may represent latent infection or reactivation disease, depending on the host [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/28\">",
"     28",
"    </a>",
"    ]. Images of cysts and tachyzoites can be found at the US Department of Agriculture website at",
"    <a class=\"external\" href=\"file://www.ars.usda.gov/Main/docs.htm?docid=11013\">",
"     file://www.ars.usda.gov/Main/docs.htm?docid=11013",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Specimens of tissue, blood, sputum, amniotic fluid, centrifuged CSF or brain tissue are stained with standard histological dyes, such as hematoxylin and eosin, Wright&rsquo;s, or Giemsa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/4,29\">",
"     4,29",
"    </a>",
"    ]. The sensitivity and specificity of these standard staining techniques for T. gondii is not well established. It is generally thought that immunohistochemistry, with the use of specific anti-toxoplasma antibody, or immunoperoxidase tests, which use antisera to T. gondii, are more sensitive and specific than routine staining techniques and may be particularly helpful for the examination of necrotic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parasites are rarely detected by histopathology in lymphadenitis, but the histopathologic pattern may suggest a diagnosis of toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/28,31,32\">",
"     28,31,32",
"    </a>",
"    ]. For example, a pattern of reactive follicular hyperplasia, clusters of epithelioid histiocytes, sinusoidal distention with monocytoid B cells would be indicative of toxoplasmosis and not malignancy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237801\">",
"    <span class=\"h2\">",
"     Tissue culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth of toxoplasma from blood or body fluids through inoculation into mice or tissue culture is diagnostic of acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]; tissue cultures are more widely available than mouse cultures, but neither is routinely available and the results may not be available for six weeks. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/4,28,34,35\">",
"     4,28,34,35",
"    </a>",
"    ]. As a result, toxoplasma cultures are not commonly performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13029276\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is the most common initial diagnostic test for acute toxoplasmosis in the immunocompetent patient or reactivation disease in the immunocompromised host. The results of serologic testing must be interpreted within the clinical context. Depending on the host and the clinical presentation, additional confirmatory testing may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237250\">",
"    <span class=\"h2\">",
"     Acute infection in the immunocompetent host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infection may be inferred through serologic testing (for both IgM and IgG antibodies), which is the most common diagnostic method that is used. A positive IgM serologic test in the appropriate clinical context (eg, immunocompetent host with cervical lymphadenopathy) would be highly suggestive of acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confirmation of acute infection can be accomplished with any of the following methodologies: IgM capture ELISA, avidity testing, or agglutination testing. (See",
"    <a class=\"local\" href=\"#H87166188\">",
"     'Avidity testing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5238977\">",
"     'Agglutination assays'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the toxoplasma IgM serologic assay is negative, acute toxoplasmosis is highly unlikely. The differential diagnosis of an immunocompetent host with cervical lymphadenopathy is broad. The most common alternative etiology would include a mononucleosis-like illness (eg, Epstein-Barr virus, cytomegalovirus, acute HIV infection). Other less common considerations include tularemia or cat-scratch disease. Alternatively, epidemiologic factors or travel history may suggest tuberculosis, secondary syphilis, African and American trypanosomiasis, or visceral leishmaniasis.",
"   </p>",
"   <p>",
"    If laboratory investigation does not establish an alternative infectious etiology, a lymph node biopsy should be performed to rule out malignancy (eg, lymphoma) or sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5237257\">",
"    <span class=\"h2\">",
"     Reactivation of infection in the immunocompromised host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients with reactivation toxoplasmosis have toxoplasma-specific IgG antibodies and negative IgM tests [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, a positive IgG titer does not distinguish reactivation disease from latent infection. For this reason, the diagnosis of central nervous system (CNS) toxoplasmosis in AIDS patients and other severely immunocompromised patients is usually made clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. AIDS patients with a suggestive clinical history, a positive specific IgG test, and typical radiographic findings (enhancing multiple brain lesions) are given a trial of anti-toxoplasma chemotherapy. Treatment of patients with toxoplasmosis usually leads to clinical and radiographic improvement within 7 to 10 days. A diagnostic brain biopsy is indicated if there is failure to improve within this time frame [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. A brain biopsy with tachyzoites would confirm the diagnosis of toxoplasmosis.",
"   </p>",
"   <p>",
"    The absence of specific IgG antibodies weighs heavily against the diagnosis of active toxoplasmosis in immunocompromised patients. A brain biopsy, without an antecedent therapeutic trial, is indicated for such patients with negative specific IgG testing for toxoplasma who have clinical features that are atypical for toxoplasmosis (eg, nonenhancing or single lesions) and among those who have been receiving prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , which is effective prophylaxis against toxoplasma infection. The approach to the HIV-infected patient with CNS lesions is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCR amplification of toxoplasma DNA in CSF has high predictive value, but relatively low sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19559/abstract/4,28,34\">",
"     4,28,34",
"    </a>",
"    ]. In addition, sometimes a lumbar puncture cannot be performed due to concerns regarding increased intracranial pressure and potential herniation in patients with cerebral edema and brain abscesses. Thus, PCR testing of CSF is usually not performed. Of note, these patients rarely have parasitemia, so PCR testing of blood has low yield in this clinical scenario. &nbsp;",
"   </p>",
"   <p>",
"    PCR testing can also be used in other body fluid samples, such as bronchoalveolar fluid in patients with suspected disseminated disease, if cytologic staining for tachyzoites is negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3871786\">",
"    <span class=\"h2\">",
"     Acute infection in the pregnant female or newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of toxoplasmosis in the pregnant female or in the newborn is covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238681\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxoplasmosis is a worldwide zoonosis caused by the intracellular protozoan parasite, Toxoplasma gondii. Laboratory testing is usually necessary to establish the diagnosis of toxoplasmosis, because the clinical manifestations of infection are so protean. (See",
"      <a class=\"local\" href=\"#H13029269\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of immunocompetent adults with primary toxoplasma infection are asymptomatic. When symptoms do occur, patients often complain of fevers, chills, and sweats in association with prominent cervical lymphadenopathy. Toxoplasmosis subsequently persists as a latent infection for the lifetime of the host. However, reactivation of toxoplasmosis can occur at any time the host becomes immunocompromised or immunosuppressed. Reactivation disease in the immunocompromised host usually occurs within the central nervous system as multiple brain abscesses. (See",
"      <a class=\"local\" href=\"#H5237188\">",
"       'General background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T. gondii infection can be diagnosed indirectly with serologic testing in the appropriate clinical context. In acute infection, IgM antibodies usually appear within one week and continue to rise. The IgM titer subsequently declines and disappears, but the rate of decline is highly variable from individual to individual. Toxoplasma-specific IgG antibodies subsequently follow within approximately two weeks of primary infection, peak within approximately eight weeks, and generally persist for life. (See",
"      <a class=\"local\" href=\"#H10842706\">",
"       'Patterns of antibody responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient with symptoms and signs of primary toxoplasmosis, a reactive toxoplasma-specific IgM antibody paired with a non-reactive IgG antibody would be highly suggestive of acute infection. In contrast, acute toxoplasmosis is highly unlikely in a patient who has a negative toxoplasma-specific IgM antibody. (See",
"      <a class=\"local\" href=\"#H10842706\">",
"       'Patterns of antibody responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In clinical practice, it is more common to see a positive result for both IgM and IgG antibodies. Although this pattern could be related to acute toxoplasmosis, clinicians should be aware that IgM antibodies can persist for months (or years) after primary infection. Thus, a reactive IgM antibody test for toxoplasmosis must always be interpreted within the clinical context. If there is clinical suspicion of acute toxoplasmosis, diagnostic confirmation should be pursued with an alternative method of diagnostic testing, (See",
"      <a class=\"local\" href=\"#H10843435\">",
"       'Interpretation of antibody testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional testing should be performed for confirmation of acute infection in patients with a positive IgM serology for toxoplasmosis, such as IgM capture ELISA, avidity testing or differential agglutination testing. (See",
"      <a class=\"local\" href=\"#H3870347\">",
"       'When to order additional testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an immunocompromised host with suspected disseminated disease, PCR testing can be a helpful aid in diagnosis, although PCR is rarely performed in immunocompetent patients presenting with cervical lymphadenopathy. (See",
"      <a class=\"local\" href=\"#H10843290\">",
"       'Polymerase chain reaction assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxoplasma may be detected on histopathology in one of two forms: tachyzoites or cysts. Tachyzoites are crescent-shaped and usually establish the diagnosis of acute infection. Cysts are circular in shape and may represent latent infection or reactivation disease, depending on the host. (See",
"      <a class=\"local\" href=\"#H5237302\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute infection may be inferred through serologic testing, which is the most common diagnostic method that is used. A positive IgM serologic test in the appropriate clinical context (eg, immunocompetent host with cervical lymphadenopathy) would be highly suggestive of acute infection. (See",
"      <a class=\"local\" href=\"#H13029276\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunocompromised patients with reactivation toxoplasmosis have toxoplasma-specific IgG antibodies and negative IgM tests. However, a positive IgG titer does not distinguish reactivation disease from latent infection. For this reason, the diagnosis of CNS toxoplasmosis in AIDS patients and other severely immunocompromised patients is usually made clinically. AIDS patients with a suggestive clinical history, a positive toxoplasma-specific IgG test, and typical radiographic findings (enhancing multiple brain lesions) are given a trial of anti-toxoplasma chemotherapy. A negative IgG serology would be strongly suggestive of an alternative diagnosis. (See",
"      <a class=\"local\" href=\"#H5237257\">",
"       'Reactivation of infection in the immunocompromised host'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/1\">",
"      Montoya JG, Remington JS. Studies on the serodiagnosis of toxoplasmic lymphadenitis. Clin Infect Dis 1995; 20:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/2\">",
"      Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 2002; 185 Suppl 1:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/3\">",
"      Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363:1965.",
"     </a>",
"    </li>",
"    <li>",
"     Garcia LS, Bruckner DA. Tissue protozoa. In: Diagnostic Medical Parasitology, Third Edition, ASM Press, Washington, DC 1997. p.111.",
"    </li>",
"    <li>",
"     Remington JS, McLeod R, Desmonts G. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant, Fourth Edition, Remington JS, Klein JO (Eds), WB Saunders, Philadelphia 1995. p.140.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/6\">",
"      Sabin AB, Feldman HA. Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science 1948; 108:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/7\">",
"      Walton BC, Benchoff BM, Brooks WH. Comparison of the indirect fluorescent antibody test and methylene blue dye test for detection of antibodies to Toxoplasma gondii. Am J Trop Med Hyg 1966; 15:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/8\">",
"      Roos T, Martius J, Gross U, Schrod L. Systematic serologic screening for toxoplasmosis in pregnancy. Obstet Gynecol 1993; 81:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/9\">",
"      Skinner LJ, Chatterton JM, Joss AW, et al. The use of an IgM immunosorbent agglutination assay to diagnose congenital toxoplasmosis. J Med Microbiol 1989; 28:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/10\">",
"      Naot Y, Desmonts G, Remington JS. IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr 1981; 98:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/11\">",
"      Verhofstede C, Van Renterghem L, Plum J. Comparison of six commercial enzyme linked immunosorbent assays for detecting IgM antibodies against Toxoplasma gondii. J Clin Pathol 1989; 42:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/12\">",
"      Hsu HW, Grady GF, Maguire JH, et al. Newborn screening for congenital Toxoplasma infection: five years experience in Massachusetts, USA. Scand J Infect Dis Suppl 1992; 84:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/13\">",
"      Lappalainen M, Koskela P, Koskiniemi M, et al. Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis 1993; 167:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/14\">",
"      Kaiser K, Van Loon AM, Pelloux H, et al. Multicenter proficiency study for detection of Toxoplasma gondii in amniotic fluid by nucleic acid amplification methods. Clin Chim Acta 2007; 375:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/15\">",
"      Wilson M, Remington JS, Clavet C, et al. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol 1997; 35:3112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/16\">",
"      Liesenfeld O, Press C, Montoya JG, et al. False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol 1997; 35:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/17\">",
"      Naot Y, Remington JS. An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis 1980; 142:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/18\">",
"      Hedman K, Lappalainen M, Sepp&auml;i&auml; I, M&auml;kel&auml; O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 1989; 159:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/19\">",
"      Bobic B, Klun I, Vujanic M, et al. Comparative evaluation of three commercial Toxoplasma-specific IgG antibody avidity tests and significance in different clinical settings. J Med Microbiol 2009; 58:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/20\">",
"      Jenum PA, Stray-Pedersen B, Gundersen AG. Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol 1997; 35:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/21\">",
"      Beghetto E, Buffolano W, Spadoni A, et al. Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy. J Clin Microbiol 2003; 41:5414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/22\">",
"      Dannemann BR, Vaughan WC, Thulliez P, Remington JS. Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. J Clin Microbiol 1990; 28:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/23\">",
"      Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. J Clin Microbiol 2004; 42:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/24\">",
"      Montoya JG, Berry A, Rosso F, Remington JS. The differential agglutination test as a diagnostic aid in cases of toxoplasmic lymphadenitis. J Clin Microbiol 2007; 45:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/25\">",
"      Dupouy-Camet J, de Souza SL, Maslo C, et al. Detection of Toxoplasma gondii in venous blood from AIDS patients by polymerase chain reaction. J Clin Microbiol 1993; 31:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/26\">",
"      Mele A, Paterson PJ, Prentice HG, et al. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant 2002; 29:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/27\">",
"      Bastien P. Molecular diagnosis of toxoplasmosis. Trans R Soc Trop Med Hyg 2002; 96 Suppl 1:S205.",
"     </a>",
"    </li>",
"    <li>",
"     Frenkel JK. Toxoplasmosis. In: Pathology of Infectious Diseases, Connor DH, Chandler FW, Schwartz DA, et al (Eds), Appleton &amp; Lange, Stamford, CT 1997. p.1261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/29\">",
"      Laibe S, Ranque S, Curtillet C, et al. Timely diagnosis of disseminated toxoplasmosis by sputum examination. J Clin Microbiol 2006; 44:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/30\">",
"      Conley FK, Jenkins KA, Remington JS. Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol 1981; 12:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/31\">",
"      McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis 1987; 9:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/32\">",
"      Eapen M, Mathew CF, Aravindan KP. Evidence based criteria for the histopathological diagnosis of toxoplasmic lymphadenopathy. J Clin Pathol 2005; 58:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/33\">",
"      Hitt JA, Filice GA. Detection of Toxoplasma gondii parasitemia by gene amplification, cell culture, and mouse inoculation. J Clin Microbiol 1992; 30:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/34\">",
"      Nash G, Kerschmann RL, Herndier B, Dubey JP. The pathological manifestations of pulmonary toxoplasmosis in the acquired immunodeficiency syndrome. Hum Pathol 1994; 25:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/35\">",
"      van de Ven E, Melchers W, Galama J, et al. Identification of Toxoplasma gondii infections by BI gene amplification. J Clin Microbiol 1991; 29:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/36\">",
"      Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/37\">",
"      Mariuz P, Bosler EM, Luft BJ. Toxoplasmosis in individuals with AIDS. Infect Dis Clin North Am 1994; 8:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/38\">",
"      Liesenfeld O, Montoya JG, Kinney S, et al. Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis 2001; 183:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19559/abstract/39\">",
"      Mathews C, Barba D, Fullerton SC. Early biopsy versus empiric treatment with delayed biopsy of non-responders in suspected HIV-associated cerebral toxoplasmosis: a decision analysis. AIDS 1995; 9:1243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14003 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19559=[""].join("\n");
var outline_f19_6_19559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5238681\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13029269\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5237188\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5237203\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5237210\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5237275\">",
"      AVAILABLE DIAGNOSTIC MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5237544\">",
"      Serologic assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10842706\">",
"      - Patterns of antibody responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10843435\">",
"      - Interpretation of antibody testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3870385\">",
"      - False negative serologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3870392\">",
"      - False positive serologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3870347\">",
"      When to order additional testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87166188\">",
"      - Avidity testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5238977\">",
"      - Agglutination assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10843290\">",
"      Polymerase chain reaction assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5237302\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5237801\">",
"      Tissue culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13029276\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5237250\">",
"      Acute infection in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5237257\">",
"      Reactivation of infection in the immunocompromised host",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3871786\">",
"      Acute infection in the pregnant female or newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5238681\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=related_link\">",
"      Congenital toxoplasmosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=related_link\">",
"      Congenital toxoplasmosis: Treatment, outcome, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_6_19560="Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency";
var content_f19_6_19560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19560/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19560/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19560/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19560/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19560/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19560/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/6/19560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This conversion is mediated by 21-hydroxylase, or in current terminology, CYP21A2.",
"   </p>",
"   <p>",
"    The most severely affected individuals with classic congenital adrenal hyperplasia due to CYP21A2 deficiency present during the neonatal period and early infancy with adrenal insufficiency with or without salt wasting, or later, with virilization. Females have genital ambiguity.",
"   </p>",
"   <p>",
"    \"Nonclassic,\" or late-onset CYP21A2 deficiency, does not manifest with neonatal genital ambiguity; rather, it presents later in life with signs of androgen excess. Clinical features in late childhood include premature pubarche, acne, and accelerated bone age; adolescent and adult females present with acne, hirsutism, and menstrual irregularity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/4-10\">",
"     4-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology, genetics, and clinical manifestations of the nonclassic form of congenital adrenal hyperplasia due to CYP21A2 deficiency are reviewed here. The diagnosis and treatment of late onset CP21A2 deficiency, and the classic form of CYP21A2 deficiency are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1367?source=see_link\">",
"     \"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon neonatal screening studies that detect classic congenital adrenal hyperplasia, CYP21A2 deficiency is a common inherited disorder. The prevalence based upon such studies has been estimated to be about 1 in 14,200 live births, ranging from 1 in 28,000 in the Chinese to 1 in 280 in Yupik Eskimos. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H2#H2\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nonclassic form (late-onset) is one of the most common autosomal recessive diseases, and the frequency is ethnic-specific. Among whites, the prevalence of the nonclassic form may be as high as 1 in 1000 to 1 in 100 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], with the prevalence being even higher among Mediterraneans, Hispanics, and Eastern European Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients with the nonclassic form will not be identified by the neonatal screening studies, which are based upon detection of very high levels of 17-hydroxyprogesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with the nonclassic form typically present with oligomenorrhea and hyperandrogenism and, therefore, may be indistinguishable from polycystic ovary syndrome (PCOS). The prevalence of congenital adrenal hyperplasia in women who present with apparent PCOS is variable, depending upon the population studied. As an example, in two different regions of Turkey, the prevalence ranged from 9.5 to 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the United States, the disorder occurs in about 1 to 4 percent of white women with clinical evidence of androgen excess [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/1,17,18\">",
"     1,17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of heterozygote carriers has been reported to be about 1 in 60 to 80 in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/11,19\">",
"     11,19",
"    </a>",
"    ], but closer to 1 in 10 in another study using mutation analysis in a European population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children who present with premature pubarche (premature development of pubic hair), the prevalence of nonclassic CYP21A2 deficiency has been reported to be very low [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/21\">",
"     21",
"    </a>",
"    ], or as high as 30 percent, in high-risk ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/22\">",
"     22",
"    </a>",
"    ]. In an unselected population of 31 such patients, none were found to have the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence in men with idiopathic oligospermia is not established. However, in one study of Jewish men presenting to an infertility clinic, there were no cases found in either 222 subjects with abnormal semen analysis or a concurrent control group of 262 men with normal semen analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol in patients with CYP21A2 deficiency results in decreased cortisol synthesis and therefore increased corticotropin (ACTH) secretion (",
"    <a class=\"graphic graphic_figure graphicRef81907 \" href=\"UTD.htm?1/15/1278\">",
"     figure 1",
"    </a>",
"    ). The resulting adrenal stimulation leads to increased production of androgens. The severity of disease relates to the degree to which the mutations compromise enzyme activity. In patients with the nonclassic form, enzymatic activity is reduced but sufficient to maintain normal glucocorticoid and mineralocorticoid production, at the expense of excessive androgen production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the other forms of congenital adrenal hyperplasia, CYP21A2 deficiency is transmitted as an autosomal recessive disorder. Humans have two CYP21A genes, a non-functional pseudogene (CYP21A1 or CYP21P) and the active gene (CYP21A2 or CYP21), both located in a 35-kilobase region of chromosome 6p21.3 within the major histocompatibility locus.",
"   </p>",
"   <p>",
"    The two CYP21A genes are more than 90 percent homologous. This high degree of homology facilitates recombination events during meiosis, with consequent exchanges of segments of DNA between the two genes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large or unequal cross-over exchanges can result in a large deletion of the active gene, or a non-functioning hybrid gene. Patients who are homozygous or heterozygous for such mutations have classic forms of CAH.",
"     </li>",
"     <li>",
"      The exchange of smaller amounts of material can result in hybrid",
"      <span class=\"nowrap\">",
"       CYP21A1/CYP21A2",
"      </span>",
"      gene products with reduced but not absent enzyme activity. A patient who is heterozygous for this and a typical large gene deletion may have nonclassic CYP21A2 deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H4#H4\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genotype versus phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not always possible to predict the phenotype of these patients from the specific mutation(s) of the CYP21A2 gene, but there are general correlations between genotype and phenotype. Patients with CYP21A2 mutations can be divided into groups according to the predicted effect of the mutation on 21-hydroxylase enzymatic activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H5#H5\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Genotype versus phenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with the late-onset form may be either compound heterozygotes (with a classic mutation and a variant allele) or heterozygotes with two variant alleles, allowing for 20 to 60 percent of normal enzymatic activity (eg, with point mutations leading to conservative amino acid substitutions such as Val281Leu).",
"   </p>",
"   <p>",
"    Women who are compound heterozygotes for two different CYP21A2 mutations usually have the phenotype associated with the less severe of the two genetic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obligate heterozygote carriers (with one normal allele) may have mild biochemical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], but no clinically important endocrine disorder.",
"   </p>",
"   <p>",
"    Despite these general correlations, the CYP21A2 deficiency phenotype does not always correlate precisely with the genotype, suggesting that other genes influence the clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H5#H5\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Genotype versus phenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prenatal diagnosis, neonatal screening and genotyping for CYP21A2 deficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with nonclassic congenital adrenal hyperplasia present after the neonatal period with signs of hyperandrogenism, without adrenal insufficiency. Clinical features may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature pubarche. Children with nonclassic CYP21A2 deficiency typically differ from children with ordinary premature adrenarche in having a bone age advanced more than 2.0 SD for age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21481?source=see_link&amp;anchor=H13#H13\">",
"       \"Premature adrenarche\", section on 'Virilizing congenital adrenal hyperplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medication-resistant cystic acne [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accelerated growth with tall stature as children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these children may enter puberty early, with early epiphyseal closure, leading to short stature as an adult, although short stature is not a consistent feature [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/1,10,31\">",
"     1,10,31",
"    </a>",
"    ]. The management of children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Female reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent and adult women have acne, hirsutism, and menstrual irregularity that are indistinguishable from the polycystic ovary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/8,32,33\">",
"     8,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 220 females with nonclassic congenital adrenal hyperplasia the clinical presentation varied by the age of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nearly all patients younger than 10 years presented with premature pubarche; clitoromegaly and acne were less common (20 percent).",
"     </li>",
"     <li>",
"      The presenting clinical features in adolescents and adult women included hirsutism (59 percent), oligomenorrhea (54 percent), acne (33 percent), infertility (13 percent), clitoromegaly (10 percent), alopecia (8 percent), and primary amenorrhea (4 percent).",
"     </li>",
"     <li>",
"      The prevalence of hirsutism increased significantly with age, from 70 percent in adolescents to 90 percent in 40 to 49 year old women. When present, the degree of hirsutism was similar at all ages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following features may help distinguish nonclassic congenital adrenal hyperplasia and polycystic ovary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonclassic congenital adrenal hyperplasia is uncommon in African-American and Hispanic-Puerto Rican women [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insulin resistance may be more severe, but probably not more common in polycystic ovarian syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polycystic ovaries on ultrasound are less common in nonclassic congenital adrenal hyperplasia (40 versus 70 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obesity is more common in women with polycystic ovary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a questionnaire-based study, women with nonclassic congenital adrenal hyperplasia show increased masculinization (defeminization) when compared to normal women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/37\">",
"     37",
"    </a>",
"    ]. These attributes were more extreme in women with the classic form of the disease. A second study using interviews and questionnaires in women with nonclassic and classic 21-hydroxylase deficiency extended these findings. Among 22 women with the classic disorder, none reported sexual fantasies or actual experience with same-sex partners, while 19 of 79 women with the nonclassic form reported sexual fantasies and 3 of 77 had same-sex encounters [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with the classic form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency have low fertility rates that correlate with the severity of the mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H12#H12\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Female reproduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, subfertility is milder in women with the nonclassic form of 21-hydroxylase deficiency. Many women conceive spontaneously, while others have anovulatory infertility that responds to glucocorticoids alone or combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the risk of spontaneous abortion (SAB) appears to be high in these women compared to normal women (&ge;25 percent versus 10 to 15 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/32,40-44\">",
"     32,40-44",
"    </a>",
"    ]. Treatment with glucocorticoids may lower this risk, as illustrated in a study of 85 women with the nonclassic form who were pursuing pregnancy. Women who had received therapy with glucocorticoids in order to conceive (n = 36), had a lower risk of SAB than those who had not received glucocorticoids (n = 49; 6.5 versus 26.3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Risk of classic CAH in offspring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with the late-onset form who seek fertility should be aware of the potential risk of giving birth to an infant with classic CYP21A2 deficiency. Women who carry the classic (severe) mutation whose partner also carries the classic mutation are at risk of having an infant who is homozygous for the severe mutation. This was illustrated in a report of 162 live births in 101 women with the late-onset form [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/40\">",
"     40",
"    </a>",
"    ]. At birth, 4 (2.5 percent) and 24 (15 percent) of the 162 infants were diagnosed with the classic form and the late-onset nonclassic form, respectively.",
"   </p>",
"   <p>",
"    If genetic screening has not been performed by a couple prior to conception, the birth of an affected infant should prompt consideration of genotyping and consideration of prenatal diagnosis in subsequent pregnancies.",
"   </p>",
"   <p>",
"    However, genotyping for CYP21 mutations is not widely available, usually not covered by insurance, and does not detect all mutations; as a result, recommendations for screening protocols for these couples have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prenatal diagnosis, neonatal screening, and genotyping for CYP21A2 deficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;In males, it can be difficult to differentiate between simple virilizing forms of \"classic\" CYP21A2 deficiency and \"non-classic\" forms. Both can present in childhood with premature pubarche or adrenarche and eventual short stature. After puberty, nonclassic men usually present with acne or infertility. Asymptomatic individuals (obligate heterozygote carriers) may be diagnosed because of an affected family member.",
"   </p>",
"   <p>",
"    Boys and men with classic CYP21A2 deficiency often develop testicular masses (testicular adrenal rest tumors). During adulthood, these are often associated with oligospermia and infertility. Although most men with the nonclassic form are thought to have normal testicular function and normal fertility, some do present with testicular adrenal rests and infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/9,10,46\">",
"     9,10,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, treatment is not necessary for men with nonclassic CYP21A2 deficiency who do not desire future fertility. However, in men with a testicular mass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oligospermia, glucocorticoid therapy should be given until fertility is no longer desired [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\", section on 'Testicular adrenal rests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adrenal incidentalomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although 60 percent of patients with unilateral adrenal incidentalomas, and even more of those with bilateral incidentalomas, have exaggerated serum 17-hydroxyprogesterone responses to ACTH stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/1\">",
"     1",
"    </a>",
"    ], the prevalence of germline CYP21A2 mutations is low. However, unilateral and bilateral adrenal incidentalomas were found in 10 of 12 patients with simple virilizing and five of seven patients with late-onset CAH, as well as 9 of 10 heterozygotic siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/48\">",
"     48",
"    </a>",
"    ]. Most tumors had a diameter of less than 2 cm, but three patients had masses more than 5 cm in size. Adrenal masses in children with CYP21A2 deficiency are usually benign [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19560/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonclassic CYP21A2 deficiency is one of the most common autosomal recessive diseases, and the frequency is ethnic-specific. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prevalence'",
"    </a>",
"    above.) The genetics of this disorder are discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children may present with precocious pubarche, medication-resistant acne, and accelerated growth. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adolescent girls and adult women, nonclassic CYP21A2 deficiency is characterized by acne, hirsutism, and menstrual irregularity (oligoovulation) that are indistinguishable from the polycystic ovary syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Children'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Female reproduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Oligo/anovulatory",
"      </span>",
"      infertility is common in women who are untreated. Most conceive with ovulation induction (glucocorticoids alone or combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate), and the rate of early pregnancy loss appears to be no higher than normal after treatment begins. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most men with the nonclassic form are thought to have normal testicular function and normal fertility, some do present with testicular adrenal rests and infertility. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/1\">",
"      White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/2\">",
"      Pang SY, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/3\">",
"      Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/4\">",
"      Mahesh VB, Greenblatt RB, Coniff RF. Adrenal hyperplasia--a case report of delayed onset of the congenital form or an acquired form. J Clin Endocrinol Metab 1968; 28:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/5\">",
"      Rosenwaks Z, Lee PA, Jones GS, et al. An attenuated form of congenital virilizing adrenal hyperplasia. J Clin Endocrinol Metab 1979; 49:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/6\">",
"      Laron Z, Pollack MS, Zamir R, et al. Late onset 21-hydroxylase deficiency and HLA in the Ashkenazi population: a new allele at the 21-hydroxylase locus. Hum Immunol 1980; 1:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/7\">",
"      Kohn B, Levine LS, Pollack MS, et al. Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 1982; 55:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/8\">",
"      Chrousos GP, Loriaux DL, Mann DL, Cutler GB Jr. Late-onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease. Ann Intern Med 1982; 96:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/9\">",
"      Chrousos GP, Loriaux DL, Sherins RJ, Cutler GB Jr. Unilateral testicular enlargement resulting from inapparent 21-hydroxylase deficiency. J Urol 1981; 126:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/10\">",
"      New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91:4205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/11\">",
"      Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/12\">",
"      Ferenczi A, Garami M, Kiss E, et al. Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/13\">",
"      Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/14\">",
"      Votava F, T&ouml;r&ouml;k D, Kov&aacute;cs J, et al. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. Eur J Endocrinol 2005; 152:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/15\">",
"      Yarman S, Dursun A, Oguz F, Alagol F. The prevalence, molecular analysis and HLA typing of late-onset 21-hydroxylase deficiency in Turkish woman with hirsutism and polycystic ovary. Endocr J 2004; 51:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/16\">",
"      Kamel N, Tonyukuk V, Emral R, et al. The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia. Endocr J 2003; 50:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/17\">",
"      Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/18\">",
"      Carmina E, Rosato F, Jann&igrave; A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/19\">",
"      Lee HH, Kuo JM, Chao HT, et al. Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese. J Clin Endocrinol Metab 2000; 85:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/20\">",
"      Baumgartner-Parzer SM, Nowotny P, Heinze G, et al. Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population. J Clin Endocrinol Metab 2005; 90:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/21\">",
"      Granoff AB, Chasalow FI, Blethen SL. 17-Hydroxyprogesterone responses to adrenocorticotropin in children with premature adrenarche. J Clin Endocrinol Metab 1985; 60:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/22\">",
"      Temeck JW, Pang SY, Nelson C, New MI. Genetic defects of steroidogenesis in premature pubarche. J Clin Endocrinol Metab 1987; 64:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/23\">",
"      Morris AH, Reiter EO, Geffner ME, et al. Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche. J Clin Endocrinol Metab 1989; 69:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/24\">",
"      Pinkas H, Fuchs S, Klipper-Aurbach Y, et al. Non-classical 21-hydroxylase deficiency: prevalence in males with unexplained abnormal sperm analysis. Fertil Steril 2010; 93:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/25\">",
"      L'Allemand D, Tardy V, Gr&uuml;ters A, et al. How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 2000; 85:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/26\">",
"      Laji S, Clauin S, Robins T, et al. Novel mutations in CYP21 detected in individuals with hyperandrogenism. J Clin Endocrinol Metab 2002; 87:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/27\">",
"      Witchel SF, Lee PA, Suda-Hartman M, et al. Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997; 82:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/28\">",
"      Gutai JP, Kowarski AA, Migeon CJ. The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. J Pediatr 1977; 90:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/29\">",
"      Charmandari E, Merke DP, Negro PJ, et al. Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. J Clin Endocrinol Metab 2004; 89:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/30\">",
"      Rose LI, Newmark SR, Strauss JS, Pochi PE. Adrenocortical hydroxylase deficiencies in acne vulgaris. J Invest Dermatol 1976; 66:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/31\">",
"      Cameron FJ, Tebbutt N, Montalto J, et al. Endocrinology and auxology of sibships with non-classical congenital adrenal hyperplasia. Arch Dis Child 1996; 74:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/32\">",
"      Stikkelbroeck NM, Hermus AR, Braat DD, Otten BJ. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003; 58:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/33\">",
"      Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/34\">",
"      Moran C, Azziz R. 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin Reprod Med 2003; 21:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/35\">",
"      Speiser PW, Dupont B, Rubinstein P, et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985; 37:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/36\">",
"      Moran C, Azziz R, Carmina E, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000; 183:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/37\">",
"      Meyer-Bahlburg HF, Dolezal C, Baker SW, et al. Gender development in women with congenital adrenal hyperplasia as a function of disorder severity. Arch Sex Behav 2006; 35:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/38\">",
"      Meyer-Bahlburg HF, Dolezal C, Baker SW, New MI. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008; 37:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/39\">",
"      Birnbaum MD, Rose LI. The partial adrenocortical hydroxylase deficiency syndrome in infertile women. Fertil Steril 1979; 32:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/40\">",
"      Moran C, Azziz R, Weintrob N, et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91:3451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/41\">",
"      Feldman S, Billaud L, Thalabard JC, et al. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 74:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/42\">",
"      Dewailly D. Nonclassic 21-hydroxylase deficiency. Semin Reprod Med 2002; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/43\">",
"      Bidet M, Bellann&eacute;-Chantelot C, Galand-Portier MB, et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/44\">",
"      Zinaman MJ, Clegg ED, Brown CC, et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/45\">",
"      Practice Committee of the American Society for Reproductive Medicine. Information on commonly asked questions about genetic evaluation and counseling for infertile couples. Fertil Steril 2004; 82 Suppl 1:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/46\">",
"      Tiitinen A, V&auml;lim&auml;ki M. Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy. J Clin Endocrinol Metab 2002; 87:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/47\">",
"      Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002; 136:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19560/abstract/48\">",
"      Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 74:685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 144 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19560=[""].join("\n");
var outline_f19_6_19560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genotype versus phenotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Female reproduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Risk of classic CAH in offspring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adrenal incidentalomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/144|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1278\" title=\"figure 1\">",
"      21 hydroxylase deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1367?source=related_link\">",
"      Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21481?source=related_link\">",
"      Premature adrenarche",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_6_19561="Lumbar puncture: Technique; indications; contraindications; and complications in adults";
var content_f19_6_19561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19561/contributors\">",
"     Kimberly S Johnson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19561/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19561/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19561/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/6/19561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quincke performed the first lumbar puncture (LP) in 1891 to relieve increased intracranial pressure in children with tuberculous meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/1\">",
"     1",
"    </a>",
"    ]. This technique subsequently became important in the diagnosis of a variety of infectious and noninfectious neurologic conditions. However, its relative value for diagnosing central nervous system (CNS) conditions other than infection has diminished as new testing methods, especially imaging techniques, have appeared.",
"   </p>",
"   <p>",
"    The indications, contraindications, and complications of LP will be reviewed here. With a few exceptions, the results of an LP are rarely diagnostic. As a result, analysis of the cerebrospinal fluid (CSF) has to be correlated with the history, physical findings, and other laboratory tests in order to be maximally useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An LP can be performed with the patient in the lateral recumbent position or sitting upright. The lateral recumbent position is preferred because it allows accurate measurement of the opening pressure.",
"   </p>",
"   <p>",
"    The choice of needle type (cutting versus atraumatic) and bore size can influence the risk of a post-LP headache, but also may increase the technical difficulty of the procedure. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link&amp;anchor=H5#H5\">",
"     \"Post-lumbar puncture headache\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The correct level of entry of the spinal needle is most easily determined with the patient sitting upright or standing. The highest points of the iliac crests should be identified visually and confirmed by palpation; a direct line joining these is a guide to the fourth lumbar vertebral body. The spinous processes of L3, L4, and L5, and the interspaces between can usually be directly identified by palpation. The spinal needle can be safely inserted into the subarachnoid space at the",
"    <span class=\"nowrap\">",
"     L3/4",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     L4/5",
"    </span>",
"    interspace, since this is well below the termination of the spinal cord.",
"   </p>",
"   <p>",
"    Correct patient positioning is an important determinant of success in obtaining CSF. The patient is instructed to remain in the fetal position with the neck, back, and limbs held in flexion. The lower lumbar spine should be flexed with the back perfectly perpendicular to the edge of a bed or examining table. The hips and legs should be parallel to each other and perpendicular to the table. Pillows placed under the head and between the knees may improve patient comfort.",
"   </p>",
"   <p>",
"    The overlying skin should be cleaned with alcohol and a disinfectant such as povidone-iodine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    (0.5 percent in alcohol 70 percent); the antiseptic should be allowed to dry before the procedure is begun. Many product inserts of chlorhexidine-containing solutions warn against use of chlorhexidine prior to lumbar puncture because of a concern that it can cause arachnoiditis. The evidence that it does so is very limited, and many experts believe that chlorhexidine has an advantage over povidone-iodine because of its onset, efficacy, and potency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Due to specific labeling prohibiting use, a formal institutional policy to support such use may be indicated. After the skin is cleaned and allowed to dry, a sterile drape with an opening over the lumbar spine is placed on the patient. Local anesthesia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) is infiltrated into the previously identified lumbar intervertebral space and a 20 or 22 gauge spinal needle containing a stylet is inserted into the lumbar intervertebral space.",
"   </p>",
"   <p>",
"    The spinal needle may be advanced slowly, angling slightly toward the head, as if aiming towards the umbilicus. The flat surface of the bevel of the needle should be positioned to face the patient's flanks to allow the needle to spread rather than cut the dural sac (the fibers of which run parallel to the spinal axis). Many physicians choose to advance the needle incrementally, removing the stylet periodically to check for CSF flow, then reinserting the stylet until the subarachnoid space is entered [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/7\">",
"     7",
"    </a>",
"    ]. However, others report a higher rate of successful LP when the stylet is removed, just after the skin is punctured and before it is passed into the subarachnoid space in order to better observe the flow of CSF upon entry of the subarachnoid space [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once CSF appears and begins to flow through the needle, the patient should be instructed to slowly straighten or extend the legs to allow free flow of CSF within the subarachnoid space. A manometer should then be placed over the hub of the needle and the opening pressure should be measured (",
"    <a class=\"graphic graphic_figure graphicRef54738 \" href=\"UTD.htm?26/27/27059\">",
"     figure 1",
"    </a>",
"    ). Fluid is then serially collected in sterile plastic tubes. A total of 8 to 15 mL of CSF is typically removed during routine LP. However, when special studies are required, such as cytology or cultures for organisms that grow less readily (eg, fungi or mycobacteria), 40 mL of fluid can safely be removed. Aspiration of CSF should not be attempted as it may increase the risk of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/7\">",
"     7",
"    </a>",
"    ]. The stylet should be replaced before the spinal needle is removed.",
"   </p>",
"   <p>",
"    No trials have shown that bed rest following LP significantly decreases the risk of post LP headache compared with immediate mobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link&amp;anchor=H9#H9\">",
"     \"Post-lumbar puncture headache\", section on 'Bedrest'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Queckenstedt maneuver can be used to demonstrate that there is free flow of fluid from the ventricles to the lumbar space. This maneuver is performed by measuring the CSF pressure and then observing the change in pressure after manual compression of both jugular veins. However, this test is rarely useful in modern practice, since newer techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) readily identify most obstructing spinal or basilar lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LP is essential or extremely useful in the diagnosis of bacterial, fungal, mycobacterial, and viral CNS infections and, in certain settings, for help in the diagnosis of subarachnoid hemorrhage, CNS malignancies, demyelinating diseases, and Guillain-Barr&eacute; syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Urgent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of definite indications for LP has decreased with the advent of better neuroimaging procedures including CT scans and MRI, but urgent LP is still indicated to diagnose two serious conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected CNS infection (with the exception of brain abscess or a parameningeal process).",
"     </li>",
"     <li>",
"      Suspected subarachnoid hemorrhage (SAH) in a patient with a negative CT scan [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/14\">",
"       14",
"      </a>",
"      ]. Since red blood cells in the CSF can reflect a traumatic tap, an important finding in this setting is xanthochromia (pink or yellow tint of the CSF supernatant), which represents hemoglobin degradation products. Xanthochromia takes at least two hours to develop. It is a highly sensitive marker of subarachnoid hemorrhage when the lumbar puncture is performed at least twelve hours after the onset of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/15\">",
"       15",
"      </a>",
"      ]. The use of CSF examination in the evaluation of a patient with suspected SAH is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H28#H28\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Lumbar puncture'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link&amp;anchor=H9#H9\">",
"       \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Color'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common use of the LP is to diagnose or exclude meningitis in patients presenting with some combination of fever, altered mental status, headache, or meningeal signs. Examination of the CSF has a high sensitivity and specificity for determining the presence of bacterial and fungal meningitis.",
"   </p>",
"   <p>",
"    The findings on CSF analysis also may help distinguish bacterial meningitis from viral infections of the central nervous system. However, there is often substantial overlap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=see_link&amp;anchor=H9#H9\">",
"     \"Viral encephalitis in adults\", section on 'Cerebrospinal fluid findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonurgent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonurgent LP is indicated in the diagnosis of the following conditions. The findings are discussed in the appropriate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic intracranial hypertension (pseudotumor cerebri)",
"     </li>",
"     <li>",
"      Carcinomatous meningitis",
"     </li>",
"     <li>",
"      Tuberculous meningitis",
"     </li>",
"     <li>",
"      Normal pressure hydrocephalus",
"     </li>",
"     <li>",
"      CNS syphilis",
"     </li>",
"     <li>",
"      CNS vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conditions in which LP is rarely diagnostic but still useful include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple sclerosis",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome",
"     </li>",
"     <li>",
"      Paraneoplastic syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LP is also required as a therapeutic or diagnostic maneuver in the following situations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/12,13,16,17\">",
"     12,13,16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spinal anesthesia",
"     </li>",
"     <li>",
"      Intrathecal administration of chemotherapy",
"     </li>",
"     <li>",
"      Intrathecal administration of antibiotics",
"     </li>",
"     <li>",
"      Injection of contrast media for myelography or for cisternography",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no absolute contraindications to performing the procedure, caution should be used in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Possible raised intracranial pressure",
"     </li>",
"     <li>",
"      Thrombocytopenia or other bleeding diathesis (including ongoing anticoagulant therapy)",
"     </li>",
"     <li>",
"      Suspected spinal epidural abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are discussed in detail in relation to the complications with which they are associated. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LP is a relatively safe procedure, but minor and major complications can occur even when standard infection control measures and good technique are used. These complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Post-LP headache",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Bleeding",
"     </li>",
"     <li>",
"      Cerebral herniation",
"     </li>",
"     <li>",
"      Minor neurologic symptoms such as radicular pain or numbness",
"     </li>",
"     <li>",
"      Late onset of epidermoid tumors of the thecal sac",
"     </li>",
"     <li>",
"      Back pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of complications was studied in a cohort of 376 patients who underwent LP for evaluation of acute cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/18\">",
"     18",
"    </a>",
"    ]. The following frequency of complications was noted: backache (25 percent), headache (22 percent), headache and backache (12 percent), severe radicular pain (15 percent), and paraparesis (1.5 percent). Severe pain or paraparesis occurred in 6.7 percent of patients receiving anticoagulants following the procedure and in none of the 34 patients who did not receive anticoagulants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Post LP headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache, which occurs in 10 to 30 percent of patients, is one of the most common complications following LP. Post-LP headache is caused by leakage of CSF from the dura and traction on pain-sensitive structures. Patients characteristically present with frontal or occipital headache within 24 to 48 hours of the procedure, which is exacerbated in an upright position and improved in the supine position. Associated symptoms may include nausea, vomiting, dizziness, tinnitus, and visual changes.",
"   </p>",
"   <p>",
"    This risk factors, prevention, and treatment of post-LP headache are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link\">",
"     \"Post-lumbar puncture headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis is an uncommon complication of LP. In a review of 179 cases of post-LP meningitis reported in the medical literature between 1952 and 2005, half of all cases occurred after spinal anesthesia; only 9 percent occurred after diagnostic LP. The most commonly isolated causative organisms were streptococcus salivarius (30 percent), streptococcus viridans (29 percent), alpha-hemolytic strep (11 percent), staphylococcus aureus (9 percent), and pseudomonas aeruginosa (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some cases of post-LP meningitis due to staphylococci, pseudomonas, and other gram-negative bacilli have been attributed to contaminated instruments or solutions or poor technique [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/20\">",
"     20",
"    </a>",
"    ], other studies have suggested that post-LP meningitis could arise from aerosolized oropharyngeal secretions from personnel present during the procedure especially since many of the causative organisms are found in the mouth and upper airway [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/19,21-23\">",
"     19,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, some authors have recommended the routine use of face masks during LP and neuroradiologic imaging procedures involving LP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Others have questioned the practicality and necessity of the use of face masks since there is no proof that face masks prevent such infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]. In 2005 the Healthcare Infection Control Advisory Committee recommended that face masks be used by individuals who place a catheter or inject material into the spinal canal, and in 2007 the CDC endorsed this recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/28\">",
"     28",
"    </a>",
"    ]. These guidelines do not require use of a face mask for routine diagnostic LP. However, we believe a face mask can reasonably be used for diagnostic procedures especially if the procedure is likely to be prolonged or difficult, or if the person carrying out the procedure has an upper respiratory tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because meningitis can be caused in animals by performing an LP after first inducing a bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], several authors have speculated that an LP in a bacteremic patient without preexisting meningitis might actually cause meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/31\">",
"     31",
"    </a>",
"    ]. However, this phenomenon is rare, if it occurs at all. In a retrospective study of 1089 bacteremic infants, the incidence of spontaneous meningitis in children who underwent LP and subsequently developed meningitis was not statistically different from those who did not undergo LP (2.1 versus 0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/32\">",
"     32",
"    </a>",
"    ]. We agree with other authors that theoretical concerns about inducing meningitis in patients with bacteremia should not be used as the basis to forego LP if meningitis is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An LP through a spinal epidural abscess can result in the spread of bacteria into the subarachnoid space. Because an LP is not needed for diagnosis, the procedure should NOT be performed in most patients with suspected epidural abscess in the lumbar region [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are rare anecdotal case reports of discitis and vertebral osteomyelitis following LP. Most cases were due to normal skin flora such as Propionibacterium species and coagulase negative staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. These complications presumably result from direct inoculation of bacteria into the vertebral bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CSF is normally acellular, although up to five red blood cells (RBCs) are considered normal after LP due to incidental trauma to a capillary or venule. A higher number of RBCs is seen in some patients in whom calculation of the white blood cell (WBC) to RBC ratio and the presence or absence of xanthochromia may differentiate LP-induced from true CNS bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link&amp;anchor=H10#H10\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious bleeding that results in spinal cord compromise has occurred in up to 1 to 2 percent of patients in some case series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/18,37\">",
"     18,37",
"    </a>",
"    ]. The diagnosis of spinal hematoma is complicated by the concealed nature of the bleeding; thus, a high index of suspicion must be maintained. Patients who have persistent back pain or neurologic findings (eg, weakness, decreased sensation, or incontinence) after undergoing LP require urgent evaluation (usually spinal magnetic resonance imaging (MRI)) for possible spinal hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/38\">",
"     38",
"    </a>",
"    ]. The appropriate treatment for patients with significant or progressing neurologic deficits is prompt surgical intervention, usually a laminectomy, and evacuation of the blood. Timely decompression of the hematoma is essential to avoid permanent loss of neurologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Patients with mild symptoms or early signs of recovery may be managed conservatively with vigilant monitoring;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may be administered to mitigate against neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H18#H18\">",
"     \"Disorders affecting the spinal cord\", section on 'Spinal epidural hematoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have thrombocytopenia or other bleeding disorders or in those who received anticoagulant therapy prior to or immediately after undergoing LP have an increased risk of bleeding. In a series cited above, spinal hematoma developed in 7 of 342 patients (2 percent) who received anticoagulant therapy after undergoing LP; five of these patients developed paraparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/18\">",
"     18",
"    </a>",
"    ]. In one literature review, 47 percent of 21 published cases of spinal hematoma following lumbar puncture occurred in patients with a coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, a high index of suspicion of spinal hematoma should be maintained in all patients who develop neurologic symptoms after a lumbar puncture, including those with no known coagulopathy. In rare cases, intraventricular, intracerebral, and subarachnoid hemorrhage have also been reported as complications of lumbar puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We are unaware of any study that examined the risk of bleeding following LP based upon the degree of thrombocytopenia or clotting study abnormalities. Thus, at present the only guidepost is \"clinical judgment.\" We generally advise NOT performing an LP in patients with coagulation defects who are actively bleeding, have severe thrombocytopenia (eg, platelet counts &lt;50,000 to",
"    <span class=\"nowrap\">",
"     80,000/&micro;L),",
"    </span>",
"    or an INR &gt;1.4, without correcting the underlying abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. When an LP is considered urgent and essential in a patient with an abnormal INR or platelet count in whom the cause is not obvious, consultation with a hematologist may provide the best advice for safe correction of the coagulopathy prior to performing the LP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=see_link&amp;anchor=H33#H33\">",
"     \"Evaluation and management of thrombocytopenia by primary care physicians\", section on 'Invasive procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For elective procedures in a patient receiving systemic anticoagulation, observational studies and expert opinion have suggested stopping unfractionated intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    drips two to four hours, stopping low-molecular-weight heparin 12 to 24 hours, and stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    five to seven days before spinal anesthesia or LP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This presumes that the underlying indications for anticoagulation therapy allow a temporary suspension of treatment. While the optimal timing of restarting anticoagulation after LP is not known, the incidence of spinal hematoma in the above-mentioned series was much lower when anticoagulation was started at least one hour after the LP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/18\">",
"     18",
"    </a>",
"    ]. Subcutaneous heparin administration is not believed to pose a substantial risk for bleeding after LP if the total daily dose is less than 10,000 units.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    has not been shown to increase the risk of serious bleeding following LP. In a prospective study of 924 patients who underwent orthopedic procedures with spinal or epidural anesthesia, 386 patients were taking antiplatelet therapy prior to surgery; 193 were taking aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/48\">",
"     48",
"    </a>",
"    ]. Neither aspirin nor any other antiplatelet agents were associated with an increased risk of bleeding. However, none of these patients was taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , or a GP",
"    <span class=\"nowrap\">",
"     IIa/IIIb",
"    </span>",
"    receptor antagonist. Female gender, increased age, a history of excessive",
"    <span class=\"nowrap\">",
"     bruising/bleeding,",
"    </span>",
"    hip surgery, continuous catheter anesthetic technique, large needle gauge, multiple needle passes, and moderate or difficult needle placement were all significant risk factors for minor bleeding at the site of catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/48\">",
"     48",
"    </a>",
"    ]. Given the unknown risk of bleeding with thienopyridine derivatives (clopidogrel, ticlopidine) it may be reasonable to suspend treatment with these agents, when possible, for one to two weeks prior to an elective LP, while pharmacologic data suggests that for GP",
"    <span class=\"nowrap\">",
"     IIa/IIIb",
"    </span>",
"    receptor antagonists, a shorter period of treatment cessation (8 hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    and 24 to 48 hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ) may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all cases, the relative risk of performing an LP has to be weighed against the potential benefit (eg, diagnosing meningitis due to an unusual or difficult to treat pathogen). In cases in which LP is considered necessary but the risk of bleeding is considered to be high, it may be useful to perform the procedure under fluoroscopy to reduce the chance of accidental injury to small blood vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cerebral herniation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious complication of LP is cerebral herniation. Suspected increased intracranial pressure (ICP) is a relative contraindication to performance of an LP and also requires independent assessment and treatment. The magnitude of the risk was evaluated in a report of 129 patients with increased ICP: 15 patients (12 percent) had an unfavorable outcome within 48 hours of LP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/49\">",
"     49",
"    </a>",
"    ]. Similar findings were noted in a series of 55 patients with subarachnoid hemorrhage: seven patients (13 percent) experienced neurologic deterioration during or soon after an LP, six of whom had evidence of cerebral dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/50\">",
"     50",
"    </a>",
"    ]. Cardiorespiratory collapse, loss of consciousness, and death may follow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 1969 study of 30 patients with increased ICP who deteriorated after LP attempted to identify the clinical features of patients who were at greatest risk for this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/51\">",
"     51",
"    </a>",
"    ]. The following findings were noted: 73 percent had focal findings on neurologic examination (including dysphagia, hemiparesis, and cranial nerve palsies); 30 percent had documented papilledema prior to the LP; and 30 percent had evidence of increased ICP on plain skull films (erosion of the posterior clinoid processes). Deterioration occurred immediately in one-half of the patients, with the remainder declining within 12 hours.",
"   </p>",
"   <p>",
"    The concern about this serious complication has resulted in routine CT scanning prior to LP being the standard of care in many emergency departments. At one institution, for example, 78 percent of patients with suspected meningitis underwent CT scanning before the LP was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/52\">",
"     52",
"    </a>",
"    ]. However, this practice, when applied to patients with suspected bacterial meningitis, delays the performance of LP, which in turn may delay treatment or limit the diagnostic power of CSF analysis when performed after antibiotic administration. Moreover, CT scanning is not necessary in all patients prior to LP and may not be adequate to exclude elevated ICP in others [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Some studies suggest that high-risk patients can be identified, allowing the majority of patients to safely undergo LP without screening CT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/52,55\">",
"     52,55",
"    </a>",
"    ]. This was best illustrated in a prospective study of 301 adults with suspected meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/52\">",
"     52",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 235 (78 percent) who underwent CT scan before LP, 24 percent had an abnormal finding but only 5 percent (11 patients) had a mass effect.",
"     </li>",
"     <li>",
"      The risk of an abnormal CT scan was associated with specific clinical features (presence of impaired cellular immunity, history of previous central nervous system disease, or a seizure within the previous week), as well as certain findings on neurologic examination (reduced level of consciousness, and focal motor or cranial abnormalities).",
"     </li>",
"     <li>",
"      Among 96 patients with none of these abnormalities, only three had an abnormal CT scan; one of the three misclassified patients had a mild mass effect but all three underwent LP without herniation.",
"     </li>",
"     <li>",
"      Compared to patients who did not undergo CT scan before LP, those who underwent CT scan before LP had an average of a two-hour delay in diagnosis and a one-hour delay in therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, we do NOT perform a CT scan before an LP in patients with suspected bacterial meningitis unless one or more risk factors is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mentation",
"     </li>",
"     <li>",
"      Focal neurologic signs",
"     </li>",
"     <li>",
"      Papilledema",
"     </li>",
"     <li>",
"      Seizure within the previous week",
"     </li>",
"     <li>",
"      Impaired cellular immunity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with these clinical risk factors should have a CT scan to identify possible mass lesion and other causes of increased ICP. Mass lesions causing elevated ICP are usually easily identified on CT scan. However, the CT scan should also be scrutinized for more subtle signs including diffuse brain swelling as manifest by loss of differentiation between gray and white matter and effacement of sulci, as well as ventricular enlargement and effacement of the basal cisterns [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Independent of the decision to perform LP, patients with possible elevated ICP based upon the above clinical features may require urgent life-saving interventions to lower ICP that may include head elevation, hyperventilation to a PCO2 of 26 to 30 mmHg, and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    (1 to 1.5",
"    <span class=\"nowrap\">",
"     g/kg).",
"    </span>",
"    When indicated, these should NOT await CT scan. The evaluation and management of patients with elevated ICP is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Urgent situations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the LP is delayed or deferred in the setting of suspected bacterial meningitis, it is important to obtain blood cultures (which reveal the pathogen in more than half of patients) and promptly institute antibiotic therapy. Urgent evaluation and treatment of increased intracranial pressure, along with the administration of antibiotics and steroids, should be instituted promptly when this is suspected. Specific treatments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Avoidance of delay'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Epidermoid tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of an epidermoid spinal cord tumor is a rare complication of LP that may become evident years after the procedure is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Most reported cases are children ages 5 to 12 years who had a LP in infancy; however this has also been described in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. It may be caused by epidermoid tissue that is transplanted into the spinal canal during LP without a stylet, or with one that is poorly fitting. This complication probably can be avoided by using spinal needles with tight-fitting stylets during LP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Abducens palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both unilateral and bilateral abducens palsy are reported complications of LP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. This is believed to result from intracranial hypotension and is generally accompanied by other clinical features of post LP headache. Most patients recover completely within days to weeks. Other cranial nerve palsies are rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radicular symptoms and low back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not uncommon (13 percent in one series) for patients to experience transient electrical-type pain in one leg during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/69\">",
"     69",
"    </a>",
"    ]. However, more sustained radicular symptoms or radicular injury appear to be rare [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to one-third of patients complain of localized back pain after LP; this may persist for several days, but rarely beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19561/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/23/44402?source=see_link\">",
"       \"Patient information: Lumbar puncture (spinal tap) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture (LP) is essential or extremely useful in the diagnosis of bacterial, fungal, mycobacterial, and viral CNS infections and, in certain settings, for help in the diagnosis of subarachnoid hemorrhage, CNS malignancies, demyelinating diseases, and Guillain-Barr&eacute; syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LP is a relatively safe procedure, but minor and major complications can occur, including headache, infection, bleeding, cerebral herniation, as well as minor neurologic symptoms such as radicular pain or numbness.",
"     </li>",
"     <li>",
"      Meningitis is a relatively rare complication of LP. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Meningitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      LP is contraindicated in patients with a suspected spinal epidural abscess.",
"     </li>",
"     <li>",
"      Suspected bacteremia is NOT a contraindication to LP.",
"     </li>",
"     <li>",
"      We suggest the use of a face mask for diagnostic LP if the procedure is expected to be prolonged or difficult or if the operator has an upper respiratory tract infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding in the epidural or subdural space following LP may occur in up to 2 percent of patients, primarily in those patients with thrombocytopenia or other bleeding disorders or in those who have received anticoagulant therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and nonsteroidal anti-inflammatory agents is NOT clearly associated with an increased risk of bleeding after LP. The bleeding risk associated with thienopyridine derivatives or GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa-receptor",
"      </span>",
"      antagonists is unknown. It is reasonable to suspend therapy, when possible, prior to elective LP.",
"     </li>",
"     <li>",
"      Anticoagulation therapy is generally suspended, when possible, prior to elective LP.",
"     </li>",
"     <li>",
"      We recommend NOT performing an LP in patients with coagulation defects who are actively bleeding, have severe thrombocytopenia (eg, platelet counts &lt;50,000 to",
"      <span class=\"nowrap\">",
"       80,000/&micro;L),",
"      </span>",
"      or an INR &gt;1.4, without correcting the underlying abnormalities.",
"     </li>",
"     <li>",
"      When an LP is considered essential in this setting, consultation with a hematologist may provide the best advice for safe correction of the coagulopathy prior to LP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebral herniation is a rare, but usually fatal, complication of an LP performed in an individual with increased intracranial pressure (ICP). While routine neuroimaging, usually brain computed tomography (CT), before LP is not indicated in all patients, those with suspected increased intracranial pressure (altered mentation, focal neurologic signs, papilledema, recent seizure, and impaired cellular immunity) should have a CT scan to rule out possible mass lesion and other causes of increased intracranial pressure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cerebral herniation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Independent of a decision to perform LP, patients with suspected elevated ICP may require urgent interventions to lower ICP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H21#H21\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Urgent situations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the LP is delayed or deferred in a patient with suspected meningitis, it is important to obtain blood cultures and promptly institute antibiotic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H6#H6\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Avoidance of delay'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Quincke HI. Lumbar puncture. In: Diseases of the nervous system, Church A.  (Ed), Appleton, New York 1909. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/2\">",
"      Scott M, Stones J, Payne N. Antiseptic solutions for central neuraxial blockade: which concentration of chlorhexidine in alcohol should we use? Br J Anaesth 2009; 103:456; author reply 456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/3\">",
"      Hebl JR. The importance and implications of aseptic techniques during regional anesthesia. Reg Anesth Pain Med 2006; 31:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/4\">",
"      Arendt KW, Segal S. Present and emerging strategies for reducing anesthesia-related maternal morbidity and mortality. Curr Opin Anaesthesiol 2009; 22:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/5\">",
"      Greenberg BM, Williams MA. Infectious complications of temporary spinal catheter insertion for diagnosis of adult hydrocephalus and idiopathic intracranial hypertension. Neurosurgery 2008; 62:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/6\">",
"      Sakuragi T, Yanagisawa K, Dan K. Bactericidal activity of skin disinfectants on methicillin-resistant Staphylococcus aureus. Anesth Analg 1995; 81:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/7\">",
"      Ellenby MS, Tegtmeyer K, Lai S, Braner DA. Videos in clinical medicine. Lumbar puncture. N Engl J Med 2006; 355:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/8\">",
"      Agrawal D. Lumbar puncture. N Engl J Med 2007; 356:424; author reply 425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/9\">",
"      Baxter AL, Fisher RG, Burke BL, et al. Local anesthetic and stylet styles: factors associated with resident lumbar puncture success. Pediatrics 2006; 117:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/10\">",
"      Thoennissen J, Herkner H, Lang W, et al. Does bed rest after cervical or lumbar puncture prevent headache? A systematic review and meta-analysis. CMAJ 2001; 165:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/11\">",
"      Sudlow C, Warlow C. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev 2002; :CD001790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/12\">",
"      Gorelick PB, Biller J. Lumbar puncture. Technique, indications, and complications. Postgrad Med 1986; 79:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/13\">",
"      The diagnostic spinal tap. Health and Public Policy Committee, American College of Physicians. Ann Intern Med 1986; 104:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/14\">",
"      Vermeulen M, van Gijn J. The diagnosis of subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/15\">",
"      Vermeulen M, Hasan D, Blijenberg BG, et al. Xanthochromia after subarachnoid haemorrhage needs no revisitation. J Neurol Neurosurg Psychiatry 1989; 52:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/16\">",
"      Marton KI, Gean AD. The spinal tap: a new look at an old test. Ann Intern Med 1986; 104:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/17\">",
"      Sternbach G. Lumbar puncture. J Emerg Med 1985; 2:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/18\">",
"      Ruff RL, Dougherty JH Jr. Complications of lumbar puncture followed by anticoagulation. Stroke 1981; 12:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/19\">",
"      Baer ET. Post-dural puncture bacterial meningitis. Anesthesiology 2006; 105:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/20\">",
"      SWARTZ MN, DODGE PR. BACTERIAL MENINGITIS--A REVIEW OF SELECTED ASPECTS. I. GENERAL CLINICAL FEATURES, SPECIAL PROBLEMS AND UNUSUAL MENINGEAL REACTIONS MIMICKING BACTERIAL MENINGITIS. N Engl J Med 1965; 272:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/21\">",
"      Domingo P, Mancebo J, Blanch L, et al. Iatrogenic streptococcal meningitis. Clin Infect Dis 1994; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/22\">",
"      Gelfand MS, Abolnik IZ. Streptococcal meningitis complicating diagnostic myelography: three cases and review. Clin Infect Dis 1995; 20:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/23\">",
"      Rubin L, Sprecher H, Kabaha A, et al. Meningitis following spinal anesthesia: 6 cases in 5 years. Infect Control Hosp Epidemiol 2007; 28:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/24\">",
"      Schlesinger JJ, Salit IE, McCormack G. Streptococcal meningitis after myelography. Arch Neurol 1982; 39:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/25\">",
"      de Jong J, Barrs AC. Lumbar myelography followed by meningitis. Infect Control Hosp Epidemiol 1992; 13:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/26\">",
"      Schelkun SR, Wagner KF, Blanks JA, Reinert CM. Bacterial meningitis following Pantopaque myelography. A case report and literature review. Orthopedics 1985; 8:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/27\">",
"      Williams J, Lye DC, Umapathi T. Diagnostic lumbar puncture: minimizing complications. Intern Med J 2008; 38:587.",
"     </a>",
"    </li>",
"    <li>",
"     Siegel JD, Rhinehart E, Jackson M et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings June 2007 http; ://www.cdc.gove/ncidod/dhap/pdf/isolatons2007.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/29\">",
"      PETERSDORF RG, SWARNER DR, GARCIA M. Studies on the pathogenesis of meningitis. II. Development of meningitis during pneumococcal bacteremia. J Clin Invest 1962; 41:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/30\">",
"      Austrian, CR. Experimental meningococcal meningitis. Bull Johns Hopkins Hosp 1919; 29:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/31\">",
"      Pray, LG. Lumbar puncture as a factor in the pathogenesis of meningitis. Am J Dis Child 1941; 62:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/32\">",
"      Eng RH, Seligman SJ. Lumbar puncture-induced meningitis. JAMA 1981; 245:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/33\">",
"      Reihsaus E, Waldbaur H, Seeling W. Spinal epidural abscess: a meta-analysis of 915 patients. Neurosurg Rev 2000; 23:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/34\">",
"      Abolnik IZ, Eaton JV, Sexton DJ. Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review. Clin Infect Dis 1995; 21:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/35\">",
"      Findlay L, Kemp FH. Osteomyelitis of the spine following lumbar puncture. Arch Dis Child 1943; 18:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/36\">",
"      Wald ER. Risk factors for osteomyelitis. Am J Med 1985; 78:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/37\">",
"      Glotzbecker MP, Bono CM, Wood KB, Harris MB. Postoperative spinal epidural hematoma: a systematic review. Spine (Phila Pa 1976) 2010; 35:E413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/38\">",
"      Braun P, Kazmi K, Nogu&eacute;s-Mel&eacute;ndez P, et al. MRI findings in spinal subdural and epidural hematomas. Eur J Radiol 2007; 64:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/39\">",
"      Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/40\">",
"      Lawton MT, Porter RW, Heiserman JE, et al. Surgical management of spinal epidural hematoma: relationship between surgical timing and neurological outcome. J Neurosurg 1995; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/41\">",
"      Sinclair AJ, Carroll C, Davies B. Cauda equina syndrome following a lumbar puncture. J Clin Neurosci 2009; 16:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/42\">",
"      Adler MD, Comi AE, Walker AR. Acute hemorrhagic complication of diagnostic lumbar puncture. Pediatr Emerg Care 2001; 17:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/43\">",
"      Lee SJ, Lin YY, Hsu CW, et al. Intraventricular hematoma, subarachnoid hematoma and spinal epidural hematoma caused by lumbar puncture: an unusual complication. Am J Med Sci 2009; 337:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/44\">",
"      Choi S, Brull R. Neuraxial techniques in obstetric and non-obstetric patients with common bleeding diatheses. Anesth Analg 2009; 109:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/45\">",
"      van Veen JJ, Nokes TJ, Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol 2010; 148:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/46\">",
"      Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 2001; 101:V141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/47\">",
"      Layton KF, Kallmes DF, Horlocker TT. Recommendations for anticoagulated patients undergoing image-guided spinal procedures. AJNR Am J Neuroradiol 2006; 27:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/48\">",
"      Horlocker TT, Wedel DJ, Schroeder DR, et al. Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia. Anesth Analg 1995; 80:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/49\">",
"      KOREIN J, CRAVIOTO H, LEICACH M. Reevaluation of lumbar puncture; a study of 129 patients with papilledema or intracranial hypertension. Neurology 1959; 9:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/50\">",
"      Duffy GP. Lumbar puncture in spontaneous subarachnoid haemorrhage. Br Med J (Clin Res Ed) 1982; 285:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/51\">",
"      Duffy GP. Lumbar puncture in the presence of raised intracranial pressure. Br Med J 1969; 1:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/52\">",
"      Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001; 345:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/53\">",
"      Shetty AK, Desselle BC, Craver RD, Steele RW. Fatal cerebral herniation after lumbar puncture in a patient with a normal computed tomography scan. Pediatrics 1999; 103:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/54\">",
"      Joffe AR. Lumbar puncture and brain herniation in acute bacterial meningitis: a review. J Intensive Care Med 2007; 22:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/55\">",
"      Gopal AK, Whitehouse JD, Simel DL, Corey GR. Cranial computed tomography before lumbar puncture: a prospective clinical evaluation. Arch Intern Med 1999; 159:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/56\">",
"      van Crevel H, Hijdra A, de Gans J. Lumbar puncture and the risk of herniation: when should we first perform CT? J Neurol 2002; 249:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/57\">",
"      Potgieter S, Dimin S, Lagae L, et al. Epidermoid tumours associated with lumbar punctures performed in early neonatal life. Dev Med Child Neurol 1998; 40:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/58\">",
"      Ziv ET, Gordon McComb J, Krieger MD, Skaggs DL. Iatrogenic intraspinal epidermoid tumor: two cases and a review of the literature. Spine (Phila Pa 1976) 2004; 29:E15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/59\">",
"      Jeong IH, Lee JK, Moon KS, et al. Iatrogenic intraspinal epidermoid tumor: case report. Pediatr Neurosurg 2006; 42:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/60\">",
"      Miyake S, Kobayashi N, Murai N, et al. Acquired lumbar epidermoid cyst in an adult. Neurol Med Chir (Tokyo) 2005; 45:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/61\">",
"      Prat Ac&iacute;n R, Galeano I. Giant occipital intradiploic epidermoid cyst associated with iatrogenic puncture. Acta Neurochir (Wien) 2008; 150:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/62\">",
"      Park JC, Chung CK, Kim HJ. Iatrogenic spinal epidermoid tumor. A complication of spinal puncture in an adult. Clin Neurol Neurosurg 2003; 105:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/63\">",
"      McDonald JV, Klump TE. Intraspinal epidermoid tumors caused by lumbar puncture. Arch Neurol 1986; 43:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/64\">",
"      Batnitzky S, Keucher TR, Mealey J Jr, Campbell RL. Iatrogenic intraspinal epidermoid tumors. JAMA 1977; 237:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/65\">",
"      B&eacute;chard P, Perron G, Larochelle D, et al. Case report: epidural blood patch in the treatment of abducens palsy after a dural puncture. Can J Anaesth 2007; 54:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/66\">",
"      Anwar S, Nalla S, Fernando DJ. Abducens nerve palsy as a complication of lumbar puncture. Eur J Intern Med 2008; 19:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/67\">",
"      Kose KC, Cebesoy O, Karadeniz E, Bilgin S. Eye problem following foot surgery--abducens palsy as a complication of spinal anesthesia. MedGenMed 2005; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/68\">",
"      Follens I, Godts D, Evens PA, Tassignon MJ. Combined fourth and sixth cranial nerve palsy after lumbar puncture: a rare complication. A case report. Bull Soc Belge Ophtalmol 2001; :29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/69\">",
"      Evans RW. Complications of lumbar puncture. Neurol Clin 1998; 16:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19561/abstract/70\">",
"      Hasegawa K, Yamamoto N. Nerve root herniation secondary to lumbar puncture in the patient with lumbar canal stenosis. A case report. Spine (Phila Pa 1976) 1999; 24:915.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4832 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-B6EAAB5947-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19561=[""].join("\n");
var outline_f19_6_19561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Urgent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonurgent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Post LP headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cerebral herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Epidermoid tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Abducens palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radicular symptoms and low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4832|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/27/27059\" title=\"figure 1\">",
"      Cerebrospinal fluid manometry",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=related_link\">",
"      Evaluation and management of thrombocytopenia by primary care physicians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/23/44402?source=related_link\">",
"      Patient information: Lumbar puncture (spinal tap) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=related_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_6_19562="Inpatient management of traumatic rib fractures";
var content_f19_6_19562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inpatient management of traumatic rib fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19562/contributors\">",
"     Eileen M Bulger, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19562/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19562/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19562/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/6/19562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/6/19562/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/6/19562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1068084880\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple rib fractures are the consequence of significant forces impacting the chest wall and are most commonly due to blunt injuries (eg, motor vehicle crash, falls, assault), but penetrating injuries (eg, gunshot) can also fracture multiple ribs. Rib fractures are present in 10 percent of all trauma patients and about 30 percent of patients with significant chest trauma. The presence of intrathoracic injury correlates directly with the number of fractured ribs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Fracture of multiple ribs in more than one location can lead to flail chest (or open chest wound) significantly compromising respiratory function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/3\">",
"     3",
"    </a>",
"    ]. The main goals in the treatment of multiple rib fractures are control of pain, support of respiratory function and stabilization of the chest wall either through mechanical ventilation or surgical fracture fixation.",
"   </p>",
"   <p>",
"    This topic review will discuss inpatient management of multiple traumatic rib fractures. The general approach to blunt chest trauma and general considerations for single or nontraumatic rib fractures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"     \"Initial evaluation and management of rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068084888\">",
"    <span class=\"h1\">",
"     TRAUMA EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial resuscitation, diagnostic evaluation, and management of the patient with blunt or penetrating injury is based upon protocols from the Advanced Trauma Life Support (ATLS&reg;) program, established by the American College of Surgeons Committee on Trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial resuscitation and evaluation of the patient with blunt or penetrating abdominal or thoracic trauma is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because an increasing number of rib fractures are clearly associated with increased morbidity and mortality, the presence of three or more rib fractures suggests the need for hospitalization or transfer to a regional trauma facility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/1,4-8\">",
"     1,4-8",
"    </a>",
"    ]. The presence of six or more rib fractures is associated with significant increases in mortality, usually due to associated injuries. Elderly patients (age &gt;65 years) are at increased risk of complications associated with rib fracture, and thus hospital admission should be considered for any elderly patient. (See",
"    <a class=\"local\" href=\"#H18698528\">",
"     'Associated injuries'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H886687\">",
"     'Morbidity and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the setting of acute trauma, many patients cannot relate their symptoms or medical history due to altered mental status (eg, neurologic injury, intoxication) or because they are intubated and sedated. Every attempt should be made to identify preexisting medical conditions by contacting the patient's primary care physician or family members. The presence of significant medical comorbidities and medical conditions requiring antiplatelet or anticoagulation should be determined, as these may impact management decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698277\">",
"    <span class=\"h2\">",
"     Physical exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings indicative of a rib fracture include rib pain upon palpation, rib step-off upon palpation, and crepitus. Multiple fractures may cause a visible chest wall deformity and the presence of paradoxical respiratory motion is diagnostic for flail chest. Pneumothorax and hemothorax are often present initially but can also develop over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial evaluation and management of rib fractures\", section on 'Clinical presentation and examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sternal fracture may accompany rib fractures when there is an anterior blow to the chest, such as an impact with the steering wheel in a motor vehicle collision. A palpable sternal step-off may be appreciated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/9\">",
"     9",
"    </a>",
"    ]. In one study, sternal fracture occurred in 7 percent of patients with flail chest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/10\">",
"     10",
"    </a>",
"    ]. Sternal fractures will usually heal without specific intervention, but require precautions (limited lifting) once the patient is up and around. Severely displaced sternal fractures may require operative intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068084913\">",
"    <span class=\"h3\">",
"     Flail chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flail chest (ie, &ldquo;stoved-in&rdquo; chest, crushed chest) occurs in 5 to 13 percent of patients with chest wall injury and is defined as the presence of three or more consecutive ribs in two or more places, which creates a floating segment in the chest wall (",
"    <a class=\"graphic graphic_figure graphicRef61518 \" href=\"UTD.htm?28/20/28996\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/11\">",
"     11",
"    </a>",
"    ]. Sternal flail occurs when the sternum becomes dissociated from the hemi-thoraces because of bilateral, multiple, anterior cartilage or rib fractures.",
"   </p>",
"   <p>",
"    The mechanism of injury is often due to a direct impact of the chest on the steering wheel or crush injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/12\">",
"     12",
"    </a>",
"    ]. Although less common, flail chest following penetrating trauma (eg, shotgun blast) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/13\">",
"     13",
"    </a>",
"    ]. Because of the severe injury mechanisms associated with flail chest, pulmonary morbidity is higher compared with multiple rib fractures without flail, and these patients are at significant risk for acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/14\">",
"     14",
"    </a>",
"    ]. Reported mortality rates are as high as 50 percent and even higher in those of advanced age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H68783394\">",
"     'Rib fracture complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Flail chest is clinically diagnosed by the observation of paradoxical motion of the chest wall with respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/15\">",
"     15",
"    </a>",
"    ]. However, because muscle splinting can conceal motion of the involved segment of ribs, a flail chest can be missed early in the clinical course. It may also be difficult to diagnose in patients who require mechanical ventilation because ventilatory support may minimize paradoxical chest wall motion. Moreover, the pattern of flail can be affected by differential recruitment of chest wall muscles.",
"   </p>",
"   <p>",
"    Paradoxical chest wall motion arises from the effect of negative pleural forces acting upon the detached segment. The rib cage normally expands upward and outward during inspiration as the diaphragm contracts and flattens, creating the negative intrathoracic pressure necessary to expand the lungs. A detailed discussion of chest wall physiology is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H2#H2\">",
"     \"Diseases of the chest wall\", section on 'Normal structure and function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With flail chest, the detached segment of the chest wall is pulled into the chest cavity during inspiration and pushed outward during expiration (",
"    <a class=\"graphic graphic_figure graphicRef79746 \" href=\"UTD.htm?23/19/23857\">",
"     figure 2",
"    </a>",
"    ). This abnormal motion increases the work of breathing and compromises respiratory function, and may necessitate intubation and ventilatory support. (See",
"    <a class=\"local\" href=\"#H1068085015\">",
"     'Pulmonary care and support'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698246\">",
"    <span class=\"h3\">",
"     Chest wall defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest wall defects occur in a variety of traumatic circumstances (eg, blast injury, shotgun injury) and are characterized by severely displaced rib fractures that visibly deform the chest wall, often associated with soft tissue loss. Paradoxical motion may not be present, especially in young patients. Tissue defects can be caused by penetrating missiles and implements or impaling objects. Initial management involves placement of a chest tube and coverage with a three-sided occlusive dressing that allows air to escape from the injury but does not allow air to draw into the chest. Subsequently, the patient with an open chest deformity will require surgical debridement and chest wall repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068084968\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain chest radiograph is one of the standard diagnostic studies performed during the primary survey during trauma resuscitation. General diagnostic considerations of the trauma patient and uncomplicated rib fractures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial evaluation and management of rib fractures\", section on 'Imaging following trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standard plain chest radiograph usually underestimates the number of rib fractures and may not detect nondisplaced fracture but will usually identify significant pneumothorax or hemothorax and, to some extent, pulmonary contusion. (See",
"    <a class=\"local\" href=\"#H68784133\">",
"     'Intrathoracic injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the chest is performed to rule out potential aortic injury based upon the mechanism of injury, or to evaluate the extent of pulmonary injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Chest CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although chest CT shows the location and number of rib fractures more reliably than chest radiograph, the information gained is not likely to significantly change rib fracture management and thus, CT should not be obtained solely to diagnose rib fractures. However, if not already performed as a part of the trauma evaluation, CT may be helpful to define pulmonary contusion or pneumothorax, or delineate anatomy when surgical intervention is contemplated. (See",
"    <a class=\"local\" href=\"#H68784637\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rib fractures of the lower rib cage (T8-T12) can be associated with intraabdominal injury and abdominal CT may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Computed tomography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\", section on 'Computed tomography (CT)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial evaluation and management of abdominal stab wounds in adults\", section on 'Computed tomography'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18698528\">",
"     'Associated injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One prospective study promotes the use of ultrasound to establish the number of rib fractures, but this approach remains operator dependent and will only become useful if it impacts management [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698528\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanisms leading to multiple rib fractures are front- or side-impact motor vehicle collisions that cause contact of the victim with the steering wheel or door. As a result, head injury, abdominal injury and extremity injury are commonly associated with chest wall injury. The presence of intrathoracic or intraabdominal injuries relates directly to the site of impact, with injured organs located directly beneath the fractured ribs. The risk of organ injury increases if two or more rib fractures are present at the same level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68784133\">",
"    <span class=\"h3\">",
"     Intrathoracic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax, hemothorax and pulmonary contusions are common in patients with multiple rib fractures. Hemothorax and pneumothorax are usually apparent upon initial presentation; however, delayed hemothorax or pneumothorax can occur.",
"   </p>",
"   <p>",
"    Displaced rib fractures can push into the lung, tearing the pulmonary pleura and lung tissue, causing pneumothorax, which occurs in about 25 percent of patients with multiple rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/1\">",
"     1",
"    </a>",
"    ]. Pneumothorax is suspected on chest auscultation as diminished breath sounds on the affected side, but may also manifest as subcutaneous emphysema with crepitus upon palpation of the chest wall. On chest radiograph, pneumothorax is diagnosed as a radiolucent space where the pulmonary parenchyma has separated from the parietal pleura. On supine radiograph, a deep sulcus sign may be more evident than apical separation. The plain film diagnosis of pneumothorax is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disruption of the intercostal vessels can lead to bleeding into the chest, particularly when multiple ribs are involved. As an example, in one study, hemothorax occurred in 81 percent of patients with &ge;2 rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in the presence of upper rib fractures, hemothorax should be assumed to be from a major vascular injury until proven otherwise, and not solely attributed to the rib fractures. In the supine position, hemothorax is identified on chest radiograph as a diffuse increase in opacification on the affected side due to the layering of blood posteriorly. The presence of hemothorax in the trauma patient indicates the need for a thoracostomy tube and a large volume of initial drainage, or ongoing bleeding may indicate the need for surgical exploration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16756020\">",
"     'Thoracostomy drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pulmonary contusion is due to the transmission of blunt force through the chest wall to the underlying lung parenchyma. Hemorrhage and alveolar collapse result, which has the appearance of focal consolidation on chest radiograph. The extent of pulmonary contusion is best evaluated on chest CT. The appearance of the injury progresses over time and follow-up imaging is needed. (See",
"    <a class=\"local\" href=\"#H1068085015\">",
"     'Pulmonary care and support'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698602\">",
"    <span class=\"h3\">",
"     Injury to abdominal organs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen and liver are the most commonly injured intra-abdominal organs following blunt trauma, occurring in 2 to 4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/10\">",
"     10",
"    </a>",
"    ]. Fractures of the right lower ribs lead to hepatic injury, fractures of the left lower ribs to splenic injury, and fractures of the posterior portion of the lower ribs to renal injury. Diagnosis and management of injury to these organs is discussed in separate topic reviews (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/54/1898?source=see_link\">",
"     \"Management of splenic injury in the adult trauma patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9497?source=see_link\">",
"     \"Management of hepatic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link\">",
"     \"Blunt genitourinary trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698609\">",
"    <span class=\"h3\">",
"     Head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head injury is a sign of a severe trauma mechanism. In one study, head injury was present in 25 percent of patients diagnosed with flail chest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/10\">",
"     10",
"    </a>",
"    ]. Of the three groups studied (flail with head injury, isolated flail, flail plus",
"    <span class=\"nowrap\">",
"     thoracic/abdominal",
"    </span>",
"    injury), patients with flail chest and head injury had significantly higher mortality compared with patients without head injury (16 versus 4 and 7 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=see_link\">",
"     \"Management of acute severe traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=see_link\">",
"     \"Skull fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698616\">",
"    <span class=\"h3\">",
"     Upper extremity injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of injury combining multiple rib fractures and upper extremity injury is typically a side impact automobile collision. Lateral chest wall fractures, pulmonary contusion, and upper extremity injury including clavicular fracture, scapular fracture, shoulder injury (eg, shoulder dislocation), and long bone fracture can occur. In one study, flail chest was associated with clavicular fracture in 8 percent of patients, and other upper extremity injuries were present in 4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/10\">",
"     10",
"    </a>",
"    ]. The diagnosis and management of upper extremity injuries is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=see_link\">",
"     \"Clavicle fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29543?source=see_link\">",
"     \"Proximal humeral fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27510?source=see_link\">",
"     \"Midshaft humeral fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68783394\">",
"    <span class=\"h1\">",
"     RIB FRACTURE COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68783402\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia is one of the most common complications associated with rib fractures. Pneumonia rates vary depending on the number of fractures and age of the patient. The incidence of pneumonia for all patients hospitalized with one or more rib fractures is about 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients admitted to a trauma center (presumably more severe injuries), the incidence is greater. Two retrospective studies reported pneumonia in 11 and 17 percent in patients &lt;65 years old, and 31 and 34 percent in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68783409\">",
"    <span class=\"h2\">",
"     Retained hemothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retained hemothorax refers to the presence of",
"    <span class=\"nowrap\">",
"     blood/clot",
"    </span>",
"    in the thoracic cavity that persists in spite of thoracostomy drainage. The risk of empyema is increased in patients with retained hemothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H68783416\">",
"     'Empyema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most accurate means to diagnose a retained hemothorax is by computed tomography of the chest. Many authors have advocated early video-assisted thoracoscopic surgery (VATS) to provide adequate drainage of the chest in these circumstances. In one trial, patients treated with early evacuation by VATS had a significantly shortened duration of chest tube drainage, fewer hospital days, and lower total hospital costs compared with patients randomized to receive a second thoracostomy tube [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, implementation of a clinical pathway (patients with residual hemothorax on postoperative day two were drained with VATS), resulted in shorter hospital stay and decreased costs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Trapped lung'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39637?source=see_link\">",
"     \"Therapeutic uses of medical thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although streptokinase and tissue plasminogen activator are used to treat retained hemothorax in other settings, these modalities should",
"    <strong>",
"     not",
"    </strong>",
"    be used in the setting of acute injury due to the risk of hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68783416\">",
"    <span class=\"h2\">",
"     Empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empyema is an infected pleural fluid collection and is estimated to occur in 3 to 10 percent of patients after the placement of a thoracostomy tube for chest trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. Independent predictors of post-traumatic empyema include prolonged duration of the thoracostomy tube, length of stay in an intensive care unit, the need for laparotomy, and the presence of pulmonary contusion or retained hemothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/22\">",
"     22",
"    </a>",
"    ]. In one study, empyema occurred in 33 percent of patients who had retained hemothorax, compared with 2 percent of patients without [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/19\">",
"     19",
"    </a>",
"    ]. The diagnosis and management of empyema is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies have suggested that prophylactic antibiotics in some trauma patients at the time of thoracostomy tube placement can reduce the risk of empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/23\">",
"     23",
"    </a>",
"    ]. The placement and management of chest tubes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68783437\">",
"    <span class=\"h2\">",
"     Fracture nonunion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small percentage of rib fractures do not heal even though a fibrous capsule may envelope the fracture. A nonunion may present months to years after injury and can cause discomfort with respiration due to movement of the fracture site. Some patients find the respiratory restriction due to pain quite disabling.",
"   </p>",
"   <p>",
"    A small number of case series describe operative fixation to manage pain and disability in patients with nonunion of traumatic rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The fibrous callous enveloping the nonunion is resected, and a plate used to fixate the ribs and limit their motion and facilitate healing. Patients treated operatively appear to have had good relief of their symptoms. (See",
"    <a class=\"local\" href=\"#H68784637\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3779491\">",
"    <span class=\"h2\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alteration in chest wall mechanics due to multiple rib fractures increases the work of breathing and the patients with multiple rib fractures are at risk for pulmonary fatigue. Respiratory failure can be due to the chest wall injury (eg, flail chest), but more commonly, it is due to an underlying pulmonary contusion or development of nosocomial pneumonia especially if superimposed upon a pre-existing pulmonary condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37673?source=see_link\">",
"     \"Management and prognosis of patients requiring prolonged mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068084976\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals of management are pain control and pulmonary volume expansion. For limited, isolated rib injuries (&lt;3 fractures), outpatient management with oral analgesics and incentive spirometry may suffice. The outpatient management of rib fractures is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and management of rib fractures\", section on 'Disposition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multidisciplinary care of the patient with multiple rib fractures includes an acute pain service for pain management, respiratory therapy to improve volume expansion and assist with ventilator management, physical therapy to increase patient mobility, and nutritional support to optimize wound healing.",
"   </p>",
"   <p>",
"    A multidisciplinary approach to patients with multiple rib fractures is associated with improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In a prospective study of patients with &ge;4 rib fractures, a multidisciplinary clinical care pathway was associated with shorter intensive care unit and hospital stays, and lower mortality compared with those who were not in the care pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16756303\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are admitted to a monitored unit or intensive care unit depending upon the number of rib fractures, nature and severity of associated injuries and the nature of medical comorbidities. Level of pain, oxygenation and ventilation, and respiratory parameters (eg, incentive spirometry volume) are followed closely with continuous pulse oximetry. (See",
"    <a class=\"local\" href=\"#H1068085015\">",
"     'Pulmonary care and support'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18699979\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Judicious fluid resuscitation is also important in the management of patients with multiple rib fractures to limit pulmonary edema in contused pulmonary tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/28\">",
"     28",
"    </a>",
"    ]. Pulmonary contusion may or may not be as evident on initial chest radiograph, and a high index of suspicion for its presence based upon the mechanism of injury allows for prudent fluid administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of inpatient management in the adult trauma patient\", section on 'Pulmonary contusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68782103\">",
"    <span class=\"h2\">",
"     DVT prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma patients are high risk for developing deep vein thrombosis, and prophylaxis is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'High risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68784140\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with traumatic rib fractures may benefit from prophylactic antibiotics to limit infectious complications associated with chest tube placement. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068084984\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain control is fundamental to the management of rib fractures to decrease chest wall splinting and alveolar collapse. Patients with pain due to rib fractures seek to minimize their chest wall motion by reducing their tidal volume and coughing effort. Adequate pain management improves patient tolerance for deep breathing and coughing, which improves lung volume and clears secretions thereby decreasing the risk for pneumonia. (See",
"    <a class=\"local\" href=\"#H1068085015\">",
"     'Pulmonary care and support'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H68783402\">",
"     'Pneumonia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55281186\">",
"    <span class=\"h2\">",
"     Options for analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies have been proposed to optimize pain control in patients with rib fractures. The involvement of a dedicated pain service is critical to provide tailored therapy and monitor its effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068085000\">",
"    <span class=\"h3\">",
"     Regional anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional anesthesia techniques available for the management of multiple rib fractures include continuous epidural infusion, paravertebral block, intrapleural infusion, and intercostal nerve block. Of these, we prefer to use epidural infusion in those patients who have no contraindications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of anesthesia and anesthetic choices\", section on 'Epidural anesthesia and analgesia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=see_link\">",
"     \"Overview of peripheral nerve blocks\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698813\">",
"    <span class=\"h4\">",
"     Continuous epidural infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of epidural catheters in patients with multisystem trauma is often limited due to contraindications for epidural catheter placement (eg, spine fractures, coagulopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. When used, epidural analgesia is associated with a shorter duration of mechanical ventilation and decreased incidence of nosocomial pneumonia. All patients, but particularly older patients, managed with epidural analgesic infusion should be closely monitored for side effects.",
"   </p>",
"   <p>",
"    The most widely studied approach uses epidural catheters to infuse local anesthetics with or without the addition of narcotic agents. A systematic review and metaanalysis of eight randomized trials did not find any differences in the need for mechanical ventilation, length of intensive care unit (ICU) stay, or mortality in patients managed with epidural analgesia compared with those who were not [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the duration of mechanical ventilation was less for those managed with thoracic epidural but significantly higher rates of hypotension were found with a thoracic epidural compared with no epidural or epidural at the lumbar level. Three of the eight included studies found superior pain control associated with epidural use; however, a pooled analysis of all the data was not performed.",
"   </p>",
"   <p>",
"    Other trials not included in this metaanalysis have found improved pulmonary function and better pain scores for epidural analgesia compared with intravenous narcotics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/32-36\">",
"     32-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55281334\">",
"    <span class=\"h4\">",
"     Paravertebral block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paravertebral block is only useful for patients with unilateral rib fractures, but is associated with a lower rate of systemic hypotension. For clinicians experienced with this technique, placement of continuous infusion catheters may be technically easier to perform compared with epidural catheter placement. Two studies have found this technique to be as effective as epidural for controlling pain associated with unilateral rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H8#H8\">",
"     \"Peripheral nerve block: Techniques\", section on 'Paravertebral nerve block'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18698834\">",
"    <span class=\"h4\">",
"     Intercostal nerve blocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent intercostal nerve block can also be used to control pain associated with rib fractures, but is limited by the duration of the block and, for patients with multiple rib fractures, the need to perform the procedure at multiple intercostal levels. Repeated blockade is needed for prolonged relief. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H7#H7\">",
"     \"Peripheral nerve block: Techniques\", section on 'Intercostal nerve block'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A continuous infusion device is available that requires surgery for placement. As such, given other options for pain control, this approach is generally not applicable to the majority of multiple rib fracture patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55281272\">",
"    <span class=\"h4\">",
"     Intrapleural infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach involves infusion of local anesthetics directly into the pleural space. The catheter used to administer the anesthetic can be placed adjacent a thoracostomy tube at the time of tube placement. One placebo controlled trial study failed to find clear benefit with this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/39\">",
"     39",
"    </a>",
"    ]. Another study, which compared intrapleural with epidural analgesia, found the epidural approach associated with better pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55281398\">",
"    <span class=\"h3\">",
"     Intravenous narcotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous narcotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) are preferred over subcutaneous or intramuscular injection due to a rapid and predictable onset of action. The management of pain with intravenous narcotics is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link&amp;anchor=H6#H6\">",
"     \"Pain control in the critically ill adult patient\", section on 'Intravenous analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is no evidence specific to the management of rib fractures, intravenous nonsteroidal anti-inflammatory drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    ) can be used to supplement and reduce narcotic usage. However, these agents are avoided in patients who have a significant bleeding risk (eg, hemothorax, solid organ injury) and those with renal insufficiency or hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient controlled analgesia (PCA) is advocated for patients with rib fractures because of more timely access to pain medication by the patients and a reduced risk for excessive sedation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of postoperative pain\", section on 'Patient controlled analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55281148\">",
"    <span class=\"h2\">",
"     Choice of analgesia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We prefer to use epidural analgesia for patients who do not have contraindications to placement of a thoracic epidural catheter.",
"     </li>",
"     <li>",
"      Patients who cannot have an epidural should be managed with parenteral opioid agents administered intravenously or via patient-controlled analgesia (PCA), if possible, with consideration of supplementation with non-steroidal antiinflammatory drugs, if not contraindicated.",
"     </li>",
"     <li>",
"      For patients failing to achieve adequate pain control with intravenous agents, local anesthetic blocks are a useful option.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068085015\">",
"    <span class=\"h1\">",
"     PULMONARY CARE AND SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alteration in pulmonary mechanics associated with multiple rib fractures increases the work of breathing. As a result, the patient is at risk for respiratory muscle fatigue. Atelectasis or underlying pulmonary contusion contribute to impaired oxygen exchange as evidenced by an increased alveolar-arterial (A-a) gradient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link&amp;anchor=H5#H5\">",
"     \"Oxygenation and mechanisms of hypoxemia\", section on 'A-a oxygen gradient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16756020\">",
"    <span class=\"h2\">",
"     Thoracostomy drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemothorax or significant pneumothorax following blunt chest trauma should have a thoracostomy tube placed. For these patients, a larger size tube (32 to 36 French) should be selected because it is less likely to become occluded by thrombus. The techniques for placement and management of thoracostomy tubes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with significant hemothorax, the rate of bleeding should also be monitored. The amount of hemorrhage may be under-appreciated. Initial drainage of &gt;1500 mL of blood or ongoing bleeding at a rate &gt;200",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    are considered indications to proceed with thoracotomy to control hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/41\">",
"     41",
"    </a>",
"    ]. In patients who have significant hemorrhage not meeting the threshold for immediate surgery, a second thoracostomy tube should be placed on the ipsilateral side to monitor ongoing hemorrhage. We consider an initial drainage of &gt;10",
"    <span class=\"nowrap\">",
"     mL/kg/hr",
"    </span>",
"    to be an indication to consider a second thoracostomy tube [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/42\">",
"     42",
"    </a>",
"    ]. The presence of a second chest tube assures that ongoing bleeding will continue to be assessed in the event that one of the tubes becomes occluded.",
"   </p>",
"   <p>",
"    In the setting of multiple rib fractures, the presence of a pneumothorax large enough to be visible on chest radiograph merits placement of a thoracostomy tube. Some patients with \"occult\" pneumothorax, evident only on computed tomography of the chest, may be managed with observation in select circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/43\">",
"     43",
"    </a>",
"    ]. Any signs of significant respiratory compromise or need for positive pressure ventilation due to respiratory fatigue or general anesthesia should prompt placement of a chest tube. During placement of the chest tubes in patients with multiple rib fractures, particular attention should be given to pain control. For patients who are hemodynamically stable, conscious sedation should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link&amp;anchor=H4#H4\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16756461\">",
"    <span class=\"h2\">",
"     Volume expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple rib fractures should receive volume expansion treatments regularly. Volume expansion by noninvasive means using incentive spirometry, deep breathing and coughing are important to reduce secretions, prevent atelectasis and avoid the need for intubation. Aggressive pulmonary toilet and chest physiotherapy may be limited by chest wall pain. In this setting, there are little data to support the use of noninvasive ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H18#H18\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Lung expansion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068085030\">",
"    <span class=\"h2\">",
"     Mechanical ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have not already been intubated need to be monitored closely for respiratory fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/10,44\">",
"     10,44",
"    </a>",
"    ]. Intubation may be unavoidable and, when needed, should be done preemptively under controlled conditions to prevent morbidity associated with sudden respiratory decompensation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intubation and ventilatory support are more often needed in patients with flail chest. In one observational study, compared with patients with two rib fractures, patients with flail chest had a significantly higher need for mechanical ventilation (86 versus 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/14\">",
"     14",
"    </a>",
"    ]. Although &ldquo;internal stabilization&rdquo; of the chest wall through mechanical ventilation and positive pressure undoubtedly benefits flail patients who have developed respiratory failure, it is important to remember that not all patients with multiple rib fractures or flail chest need to be intubated, and that mechanical ventilation is associated with other risks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail to wean from mechanical ventilation may benefit from operative rib fracture fixation. (See",
"    <a class=\"local\" href=\"#H68784637\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68784637\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of surgical management are to improve respiratory mechanics, reduce pain and prevent pulmonary restriction associated with significant chest wall deformities. Although the majority of patients will heal their rib fractures with conservative measures, it is recognized that select patients may benefit from surgical rib fracture fixation.",
"   </p>",
"   <p>",
"    Patients with uncomplicated rib fractures have significant short-term disabilities and, in one study, these patients lost an average of 70 days of work [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with crush injury associated with severe chest deformities are likely to have significant long-term disability without surgical stabilization of the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several single center reviews have suggested that rib fracture stabilization may facilitate ventilator weaning, and thus shorten the duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Patients with significant pulmonary contusions were less likely to benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/51\">",
"     51",
"    </a>",
"    ]. Two small randomized trials have supported these conclusions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 37 flail chest patients to surgical stabilization or nonoperative management [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/52\">",
"       52",
"      </a>",
"      ]. All patients required mechanical ventilation. The surgically managed patients had significantly fewer days on the ventilator, shorter intensive care unit stay, a lower incidence of pneumonia, better pulmonary function at one month, and a higher percentage of patients who returned to work at six months compared with the nonoperative group.",
"     </li>",
"     <li>",
"      Another trial randomly assigned 40 patients with flail chest to surgical fixation or an external adhesive plaster [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/53\">",
"       53",
"      </a>",
"      ]. The operative group demonstrated significantly fewer patients requiring mechanical ventilation, fewer days in the intensive care unit, shorter hospital stay, and a lower incidence of pneumonia compared with the conservatively managed group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In spite of these results, the EAST Trauma practice guidelines recognize surgical fixation as only a Level III recommendation for management of flail chest given the small numbers of patients randomized and a lack of generalizability due to strict exclusion criteria, and the absence of trials comparing operative repair with &lsquo;&lsquo;modern&rsquo;&rsquo; nonoperative treatments such as epidural anesthesia and chest physiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/54\">",
"     54",
"    </a>",
"    ]. As such, fracture fixation is not widely practiced. A survey of trauma and thoracic surgeons in the United States suggested that the majority felt that rib fracture fixation was appropriate for selected patients, yet only 26 percent of these surgeons had been involved in such a case [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/55\">",
"     55",
"    </a>",
"    ] .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068085046\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally accepted indications for operative rib fixation include the presence of [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A flail segment in a patient with failure to wean from mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H1068084913\">",
"       'Flail chest'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1068085030\">",
"       'Mechanical ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Painful, movable ribs refractory to pain management strategies. (See",
"      <a class=\"local\" href=\"#H1068084984\">",
"       'Pain management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant chest wall deformity or presence of a tissue defect [",
"      <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/52,56\">",
"       52,56",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18698246\">",
"       'Chest wall defect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest wall instability due to nonunion of rib fractures. (See",
"      <a class=\"local\" href=\"#H68783437\">",
"       'Fracture nonunion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significantly displaced ribs found at thoracotomy being performed for other reasons (eg, open pneumothorax, pulmonary laceration, retained hemothorax, diaphragm hernia, vascular injury). This is referred to as \"on the way out fixation\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H893841\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for surgical stabilization for patients with severe pulmonary contusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/15,51,54,57\">",
"     15,51,54,57",
"    </a>",
"    ]. The purpose of stabilization is to facilitate ventilator weaning. Thus, if the patient has a significant underlying pulmonary contusion that will prevent weaning within a reasonable period of time, there would be little benefit to the procedure. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H886646\">",
"    <span class=\"h2\">",
"     Rib fracture stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rib fracture fixation has traditionally required an open thoracotomy for adequate exposure. Several plate types and plate fixation methods have been used, but the search for the optimal material and fixation method continues [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rib fracture fixation is complicated by the anatomy of the human rib. Rib thickness ranges from 8 to 12 mm with a very thin cortex. As a result, it does not hold cortical screws well. In addition, the rib tends to fracture in a spiral pattern or in many small fragments (ie, comminuted), which complicate repair. Entrapment of the intercostal nerve either as a result of the injury or due to repair can lead to chronic postoperative rib pain. &nbsp;",
"   </p>",
"   <p>",
"    One approach to rib fracture fixation uses malleable plates attached to the anterior surface of the rib (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73486 \" href=\"UTD.htm?34/21/35167\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. However, fixation of these plates can be problematic. Another method of fixation uses wire cerclage (ie, wrapped around the rib) but this can be complicated by wire breakage and plate dislodgement. In addition, circumferential fixation of the rib with a permanent material can potentially impinge the intercostal nerve, causing chronic pain which may require removal of the plates. For this reason, when cerclage is necessary (ie, comminuted fracture), absorbable sutures should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/15,61,62\">",
"     15,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an alternative, screws can be used to hold the plates in place, but their use is often limited by cortical thickness. Novel techniques for rib fracture fixation include the use of contoured rib plates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/63\">",
"     63",
"    </a>",
"    ], absorbable plates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/61\">",
"     61",
"    </a>",
"    ], intramedullary rods [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/15\">",
"     15",
"    </a>",
"    ], U-plates fixed with screws placed over the top of the rib minimizing the risk to the intercostal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/64\">",
"     64",
"    </a>",
"    ], and application of osteogenic protein at the fracture site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885806\">",
"    <span class=\"h2\">",
"     Video-assisted thoracoscopic surgery (VATS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-assisted thoracoscopic surgery (VATS) has been used to aid fracture fixation, evacuate retained hemothorax, and perform repair of some associated injuries (eg, diaphragm rupture). For fracture stabilization, three-dimensional computed tomography (CT) with reconstruction of the chest wall is obtained prior to surgery to plan the approach. Muscle sparing techniques and small, localized incisions are used. These strategies may minimize the operative morbidity and increase enthusiasm for surgical rib fracture fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/66\">",
"     66",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068085062\">",
"    <span class=\"h2\">",
"     Chest wall reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large chest wall defects, such as those resulting from shotgun blasts, explosions or impalements, are a surgical challenge. Debridement of devitalized muscle, bone, skin, and removal of foreign bodies can result in a large defect over which soft tissue coverage by rotation of myocutaneous flaps is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diaphragm transposition refers to a procedure in which the diaphragm is detached from the chest wall peripherally and sutured to the intercostal muscles above the chest wall defect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/68\">",
"     68",
"    </a>",
"    ]. This procedure is used for lower chest wall defects and it effectively converts a chest wall defect to an abdominal wall defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H886687\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A greater number of rib fractures is associated with increased morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. The presence of six or more rib fractures significantly increases the risk for death, often due to associated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/6\">",
"     6",
"    </a>",
"    ]. A review of data from the National Trauma Databank confirmed an increasing risk of pulmonary complications with increasing number of rib fractures, but identified age and Injury Severity Score (ISS) as the primary predictors of death [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased number of rib fractures is more common in older patients who are clearly at a higher risk for complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/5,18,69,70\">",
"     5,18,69,70",
"    </a>",
"    ]. In one study, patients over age 45 with &ge;4 rib fractures had a significantly longer duration of mechanical ventilation and longer hospital stay compared with younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/69\">",
"     69",
"    </a>",
"    ]. These data are likely driven by an increased incidence of infectious complications in older patients. For patients &lt;65, pneumonia occurs in 11 to 17 percent, whereas, for patients &ge;65, rates up to 34 percent are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/6/19562/abstract/5,69\">",
"     5,69",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    One other study found that for each additional rib fracture in patients &gt;65, the risk of pneumonia increased by 27 percent, and mortality increased by 19 percent. (See",
"    <a class=\"local\" href=\"#H68783402\">",
"     'Pneumonia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=see_link\">",
"       \"Patient information: Rib fractures in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068085126\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple rib fractures are the consequence of significant forces impacting the chest wall and are most commonly due to blunt injuries (eg, motor-vehicle crash, falls, assault), but penetrating injuries (eg, gunshot) can also fracture ribs. (See",
"      <a class=\"local\" href=\"#H1068084880\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head injury, abdominal injury and extremity injury are commonly associated with multiple rib fractures due to the most common mechanisms of injury, which are front- or side-impact motor-vehicle collisions. The presence of intrathoracic or intraabdominal injuries relates directly to the overlying impact with injured organs located directly beneath the fractured ribs. (See",
"      <a class=\"local\" href=\"#H18698528\">",
"       'Associated injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical findings indicative of a rib fracture include rib pain with palpation, palpable rib step-offs and crepitus. Multiple fractures may cause a visible chest wall deformity. (See",
"      <a class=\"local\" href=\"#H18698277\">",
"       'Physical exam'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flail chest occurs in 5 to 13 percent of patients with chest wall injury and is defined as the presence of three or more consecutive ribs in two or more places, which creates a floating segment in the chest wall. (See",
"      <a class=\"local\" href=\"#H1068084913\">",
"       'Flail chest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard plain chest radiograph usually underestimates the number of rib fractures and may not detect nondisplaced fractures. Although computed tomography (CT) of the chest shows the location and number of rib fractures more reliably than chest radiograph, CT should not be obtained solely to evaluate rib fractures. (See",
"      <a class=\"local\" href=\"#H1068084968\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumonia is the most common complication of multiple rib fractures, occurring in up to 30 percent of patients. Other complications related directly to rib fractures include retained hemothorax, empyema, and chronic disability due to fracture nonunion or respiratory dysfunction. (See",
"      <a class=\"local\" href=\"#H68783394\">",
"       'Rib fracture complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of rib fractures includes thoracostomy drainage for pneumothorax or hemothorax and judicious administration of fluid during resuscitation to limit edema formation in contused regions of the lungs. (See",
"      <a class=\"local\" href=\"#H1068084976\">",
"       'General management issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate pain management is fundamental to improve patient tolerance for deep breathing and coughing, which improves lung volume and clears secretions, thereby decreasing the risk for pneumonia. Pain control can be achieved with a combination of regional anesthesia, intravenous narcotics, and intravenous nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H1068084984\">",
"       'Pain management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not have any contraindications, we suggest placement of a thoracic epidural catheter for the administration of epidural analgesic agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who cannot have an epidural should be managed with parenteral opioid agents administered intravenously or via patient-controlled analgesia (PCA), and supplemented with non-steroidal antiinflammatory drugs. For patients failing to achieve adequate pain control with intravenous opioid agents, local anesthetic block is a useful option. (See",
"      <a class=\"local\" href=\"#H55281148\">",
"       'Choice of analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The alteration in pulmonary mechanics associated with multiple rib fractures increases the work of breathing, placing the patient at risk for respiratory failure. Aggressive pulmonary toilet is important for volume expansion and managing secretions. Any patient who does not require immediate intubation needs to be monitored closely. Intubation may be unavoidable and, when needed, should be performed preemptively under controlled conditions. (See",
"      <a class=\"local\" href=\"#H1068085015\">",
"       'Pulmonary care and support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical fracture stabilization may be necessary under select circumstances which include the presence of a flail segment in a patient who fails to wean from mechanical ventilation, painful, movable ribs refractory to pain management strategies, significant chest wall deformity, presence of a tissue defect, chest wall instability due to nonunion of rib fractures, or displaced ribs found at the time of a thoracotomy performed for other reasons. (See",
"      <a class=\"local\" href=\"#H1068085046\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rib fracture fixation has traditionally required an open thoracotomy; however, laparoscopic techniques have also been described. Several plate types (eg, anterior, U-plate) and plate fixation methods (eg, wire or suture cerclage, screws) have been used. Multiple techniques have been used to manage the myriad of fracture configurations and no one method has been found to be superior to any other. (See",
"      <a class=\"local\" href=\"#H886646\">",
"       'Rib fracture stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality from multiple rib fractures is directly related to the number of ribs fractured, injury severity (ie, associated injuries) and age. Mortality for patients over the age of 65 approaches 25 percent. (See",
"      <a class=\"local\" href=\"#H886687\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/1\">",
"      Sirmali M, T&uuml;r&uuml;t H, Top&ccedil;u S, et al. A comprehensive analysis of traumatic rib fractures: morbidity, mortality and management. Eur J Cardiothorac Surg 2003; 24:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/2\">",
"      Liman ST, Kuzucu A, Tastepe AI, et al. Chest injury due to blunt trauma. Eur J Cardiothorac Surg 2003; 23:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/3\">",
"      Ullman EA, Donley LP, Brady WJ. Pulmonary trauma emergency department evaluation and management. Emerg Med Clin North Am 2003; 21:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/4\">",
"      Brasel KJ, Guse CE, Layde P, Weigelt JA. Rib fractures: relationship with pneumonia and mortality. Crit Care Med 2006; 34:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/5\">",
"      Bulger EM, Arneson MA, Mock CN, Jurkovich GJ. Rib fractures in the elderly. J Trauma 2000; 48:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/6\">",
"      Flagel BT, Luchette FA, Reed RL, et al. Half-a-dozen ribs: the breakpoint for mortality. Surgery 2005; 138:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/7\">",
"      Ziegler DW, Agarwal NN. The morbidity and mortality of rib fractures. J Trauma 1994; 37:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/8\">",
"      Lee RB, Bass SM, Morris JA Jr, MacKenzie EJ. Three or more rib fractures as an indicator for transfer to a Level I trauma center: a population-based study. J Trauma 1990; 30:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/9\">",
"      Recinos G, Inaba K, Dubose J, et al. Epidemiology of sternal fractures. Am Surg 2009; 75:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/10\">",
"      Athanassiadi K, Theakos N, Kalantzi N, Gerazounis M. Prognostic factors in flail-chest patients. Eur J Cardiothorac Surg 2010; 38:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/11\">",
"      LoCicero J 3rd, Mattox KL. Epidemiology of chest trauma. Surg Clin North Am 1989; 69:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/12\">",
"      Tzelepis GE, McCool FD, Hoppin FG Jr. Chest wall distortion in patients with flail chest. Am Rev Respir Dis 1989; 140:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/13\">",
"      Gamblin TC, Dalton ML. Flail chest caused by penetrating trauma: a case report. Curr Surg 2002; 59:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/14\">",
"      Velmahos GC, Vassiliu P, Chan LS, et al. Influence of flail chest on outcome among patients with severe thoracic cage trauma. Int Surg 2002; 87:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/15\">",
"      Nirula R, Diaz JJ Jr, Trunkey DD, Mayberry JC. Rib fracture repair: indications, technical issues, and future directions. World J Surg 2009; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/16\">",
"      Holmes JF, Ngyuen H, Jacoby RC, et al. Do all patients with left costal margin injuries require radiographic evaluation for intraabdominal injury? Ann Emerg Med 2005; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/17\">",
"      Chan SS. Emergency bedside ultrasound for the diagnosis of rib fractures. Am J Emerg Med 2009; 27:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/18\">",
"      Bergeron E, Lavoie A, Clas D, et al. Elderly trauma patients with rib fractures are at greater risk of death and pneumonia. J Trauma 2003; 54:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/19\">",
"      Karmy-Jones R, Holevar M, Sullivan RJ, et al. Residual hemothorax after chest tube placement correlates with increased risk of empyema following traumatic injury. Can Respir J 2008; 15:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/20\">",
"      Meyer DM, Jessen ME, Wait MA, Estrera AS. Early evacuation of traumatic retained hemothoraces using thoracoscopy: a prospective, randomized trial. Ann Thorac Surg 1997; 64:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/21\">",
"      Morrison CA, Lee TC, Wall MJ Jr, Carrick MM. Use of a trauma service clinical pathway to improve patient outcomes for retained traumatic hemothorax. World J Surg 2009; 33:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/22\">",
"      Eren S, Esme H, Sehitogullari A, Durkan A. The risk factors and management of posttraumatic empyema in trauma patients. Injury 2008; 39:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/23\">",
"      Sanabria A, Valdivieso E, Gomez G, Echeverry G. Prophylactic antibiotics in chest trauma: a meta-analysis of high-quality studies. World J Surg 2006; 30:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/24\">",
"      Anavian J, Guthrie ST, Cole PA. Surgical management of multiple painful rib nonunions in patient with a history of severe shoulder girdle trauma: a case report and literature review. J Orthop Trauma 2009; 23:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/25\">",
"      Cacchione RN, Richardson JD, Seligson D. Painful nonunion of multiple rib fractures managed by operative stabilization. J Trauma 2000; 48:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/26\">",
"      Todd SR, McNally MM, Holcomb JB, et al. A multidisciplinary clinical pathway decreases rib fracture-associated infectious morbidity and mortality in high-risk trauma patients. Am J Surg 2006; 192:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/27\">",
"      Wilson S, Bin J, Sesperez J, et al. Clinical pathways--can they be used in trauma care. An analysis of their ability to fit the patient. Injury 2001; 32:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/28\">",
"      Bastos R, Calhoon JH, Baisden CE. Flail chest and pulmonary contusion. Semin Thorac Cardiovasc Surg 2008; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/29\">",
"      Bulger EM, Edwards T, Klotz P, Jurkovich GJ. Epidural analgesia improves outcome after multiple rib fractures. Surgery 2004; 136:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/30\">",
"      Carrier FM, Turgeon AF, Nicole PC, et al. Effect of epidural analgesia in patients with traumatic rib fractures: a systematic review and meta-analysis of randomized controlled trials. Can J Anaesth 2009; 56:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/31\">",
"      Bulger, EM, Edwards, et al. Indications and Contraindications for Thoracic Epidural Analgesia in Multiply Injured Patients. Acute Pain 2008; 10:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/32\">",
"      Mackersie RC, Karagianes TG, Hoyt DB, Davis JW. Prospective evaluation of epidural and intravenous administration of fentanyl for pain control and restoration of ventilatory function following multiple rib fractures. J Trauma 1991; 31:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/33\">",
"      Mackersie RC, Shackford SR, Hoyt DB, Karagianes TG. Continuous epidural fentanyl analgesia: ventilatory function improvement with routine use in treatment of blunt chest injury. J Trauma 1987; 27:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/34\">",
"      Moon MR, Luchette FA, Gibson SW, et al. Prospective, randomized comparison of epidural versus parenteral opioid analgesia in thoracic trauma. Ann Surg 1999; 229:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/35\">",
"      Govindarajan R, Bakalova T, Michael R, Abadir AR. Epidural buprenorphine in management of pain in multiple rib fractures. Acta Anaesthesiol Scand 2002; 46:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/36\">",
"      Wisner DH. A stepwise logistic regression analysis of factors affecting morbidity and mortality after thoracic trauma: effect of epidural analgesia. J Trauma 1990; 30:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/37\">",
"      Karmakar MK, Critchley LA, Ho AM, et al. Continuous thoracic paravertebral infusion of bupivacaine for pain management in patients with multiple fractured ribs. Chest 2003; 123:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/38\">",
"      Mohta M, Verma P, Saxena AK, et al. Prospective, randomized comparison of continuous thoracic epidural and thoracic paravertebral infusion in patients with unilateral multiple fractured ribs--a pilot study. J Trauma 2009; 66:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/39\">",
"      Short K, Scheeres D, Mlakar J, Dean R. Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Am Surg 1996; 62:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/40\">",
"      Luchette FA, Radafshar SM, Kaiser R, et al. Prospective evaluation of epidural versus intrapleural catheters for analgesia in chest wall trauma. J Trauma 1994; 36:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/41\">",
"      Karmy-Jones R, Jurkovich GJ, Nathens AB, et al. Timing of urgent thoracotomy for hemorrhage after trauma: a multicenter study. Arch Surg 2001; 136:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/42\">",
"      Stewart RM, Corneille MG. Common complications following thoracic trauma: their prevention and treatment. Semin Thorac Cardiovasc Surg 2008; 20:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/43\">",
"      Ball CG, Ranson K, Dente CJ, et al. Clinical predictors of occult pneumothoraces in severely injured blunt polytrauma patients: A prospective observational study. Injury 2009; 40:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/44\">",
"      Barone JE, Pizzi WF, Nealon TF Jr, Richman H. Indications for intubation in blunt chest trauma. J Trauma 1986; 26:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/45\">",
"      Shackford SR, Smith DE, Zarins CK, et al. The management of flail chest. A comparison of ventilatory and nonventilatory treatment. Am J Surg 1976; 132:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/46\">",
"      Shackford SR, Virgilio RW, Peters RM. Selective use of ventilator therapy in flail chest injury. J Thorac Cardiovasc Surg 1981; 81:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/47\">",
"      Trinkle JK, Richardson JD, Franz JL, et al. Management of flail chest without mechanical ventilation. Ann Thorac Surg 1975; 19:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/48\">",
"      Kerr-Valentic MA, Arthur M, Mullins RJ, et al. Rib fracture pain and disability: can we do better? J Trauma 2003; 54:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/49\">",
"      Nirula R, Allen B, Layman R, et al. Rib fracture stabilization in patients sustaining blunt chest injury. Am Surg 2006; 72:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/50\">",
"      Ahmed Z, Mohyuddin Z. Management of flail chest injury: internal fixation versus endotracheal intubation and ventilation. J Thorac Cardiovasc Surg 1995; 110:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/51\">",
"      Voggenreiter G, Neudeck F, Aufmkolk M, et al. Operative chest wall stabilization in flail chest--outcomes of patients with or without pulmonary contusion. J Am Coll Surg 1998; 187:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/52\">",
"      Tanaka H, Yukioka T, Yamaguti Y, et al. Surgical stabilization of internal pneumatic stabilization? A prospective randomized study of management of severe flail chest patients. J Trauma 2002; 52:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/53\">",
"      Granetzny A, Abd El-Aal M, Emam E, et al. Surgical versus conservative treatment of flail chest. Evaluation of the pulmonary status. Interact Cardiovasc Thorac Surg 2005; 4:583.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.east.org/tpg/pulmcontflailchest.pdf (Accessed on August 05, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/55\">",
"      Mayberry JC, Ham LB, Schipper PH, et al. Surveyed opinion of American trauma, orthopedic, and thoracic surgeons on rib and sternal fracture repair. J Trauma 2009; 66:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/56\">",
"      Thomas AN, Blaisdell FW, Lewis FR Jr, Schlobohm RM. Operative stabilization for flail chest after blunt trauma. J Thorac Cardiovasc Surg 1978; 75:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/57\">",
"      Pettiford BL, Luketich JD, Landreneau RJ. The management of flail chest. Thorac Surg Clin 2007; 17:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/58\">",
"      Pacheco PE, Orem AR, Vegunta RK, et al. The novel use of Nuss bars for reconstruction of a massive flail chest. J Thorac Cardiovasc Surg 2009; 138:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/59\">",
"      Dunlop RL, Tiong W, Veerasingam D, Kelly JL. Novel use of hand fracture fixation plates in the surgical stabilisation of flail chest. J Plast Reconstr Aesthet Surg 2010; 63:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/60\">",
"      Engel C, Krieg JC, Madey SM, et al. Operative chest wall fixation with osteosynthesis plates. J Trauma 2005; 58:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/61\">",
"      Mayberry JC, Terhes JT, Ellis TJ, et al. Absorbable plates for rib fracture repair: preliminary experience. J Trauma 2003; 55:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/62\">",
"      Marasco S, Cooper J, Pick A, Kossmann T. Pilot study of operative fixation of fractured ribs in patients with flail chest. ANZ J Surg 2009; 79:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/63\">",
"      Bottlang M, Helzel I, Long WB, Madey S. Anatomically contoured plates for fixation of rib fractures. J Trauma 2010; 68:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/64\">",
"      Sales JR, Ellis TJ, Gillard J, et al. Biomechanical testing of a novel, minimally invasive rib fracture plating system. J Trauma 2008; 64:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/65\">",
"      Konstantinov IE, Saxena P, Wood DJ. Stabilisation of chronic flail chest: a novel approach of surgical fixation and osteogenesis. Thorax 2009; 64:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/66\">",
"      Richardson JD, Franklin GA, Heffley S, Seligson D. Operative fixation of chest wall fractures: an underused procedure? Am Surg 2007; 73:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/67\">",
"      Yoshino N, Yamauchi S, Akimoto M, et al. A case report on a full-thickness chest wall reconstruction with polypropylene mesh and stainless steel mesh concurrently using a transverse rectus abdominis myocutaneous flap. Ann Thorac Cardiovasc Surg 2006; 12:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/68\">",
"      Bender JS, Lucas CE. Management of close-range shotgun injuries to the chest by diaphragmatic transposition: case reports. J Trauma 1990; 30:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/69\">",
"      Holcomb JB, McMullin NR, Kozar RA, et al. Morbidity from rib fractures increases after age 45. J Am Coll Surg 2003; 196:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/6/19562/abstract/70\">",
"      Stawicki SP, Grossman MD, Hoey BA, et al. Rib fractures in the elderly: a marker of injury severity. J Am Geriatr Soc 2004; 52:805.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15152 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19562=[""].join("\n");
var outline_f19_6_19562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1068085126\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1068084880\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1068084888\">",
"      TRAUMA EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18698277\">",
"      Physical exam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1068084913\">",
"      - Flail chest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18698246\">",
"      - Chest wall defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1068084968\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18698528\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68784133\">",
"      - Intrathoracic injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18698602\">",
"      - Injury to abdominal organs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18698609\">",
"      - Head injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18698616\">",
"      - Upper extremity injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68783394\">",
"      RIB FRACTURE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68783402\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68783409\">",
"      Retained hemothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68783416\">",
"      Empyema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68783437\">",
"      Fracture nonunion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3779491\">",
"      Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1068084976\">",
"      GENERAL MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16756303\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18699979\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68782103\">",
"      DVT prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68784140\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1068084984\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55281186\">",
"      Options for analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1068085000\">",
"      - Regional anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18698813\">",
"      Continuous epidural infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H55281334\">",
"      Paravertebral block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18698834\">",
"      Intercostal nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H55281272\">",
"      Intrapleural infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55281398\">",
"      - Intravenous narcotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55281148\">",
"      Choice of analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1068085015\">",
"      PULMONARY CARE AND SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16756020\">",
"      Thoracostomy drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16756461\">",
"      Volume expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1068085030\">",
"      Mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68784637\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1068085046\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H893841\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H886646\">",
"      Rib fracture stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885806\">",
"      Video-assisted thoracoscopic surgery (VATS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1068085062\">",
"      Chest wall reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H886687\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1068085126\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15152|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/21/35167\" title=\"diagnostic image 1\">",
"      Rib fracture stabilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15152|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/20/28996\" title=\"figure 1\">",
"      Flail chest injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23857\" title=\"figure 2\">",
"      Flail chest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=related_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=related_link\">",
"      Clavicle fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=related_link\">",
"      Diagnosis and management of pleural causes of unexpandable lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=related_link\">",
"      Initial evaluation and management of abdominal stab wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=related_link\">",
"      Initial evaluation and management of rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37673?source=related_link\">",
"      Management and prognosis of patients requiring prolonged mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=related_link\">",
"      Management of acute severe traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9497?source=related_link\">",
"      Management of hepatic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/54/1898?source=related_link\">",
"      Management of splenic injury in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27510?source=related_link\">",
"      Midshaft humeral fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=related_link\">",
"      Patient information: Rib fractures in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29543?source=related_link\">",
"      Proximal humeral fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=related_link\">",
"      Skull fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39637?source=related_link\">",
"      Therapeutic uses of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_6_19563="Heparin intracerebral hem";
var content_f19_6_19563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Heparin in primary intracerebral hemorrhage: results of two prospective studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day 10 heparin* n = 23",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day 4 heparin n = 23",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day 2 heparin n = 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic pulmonary embolism",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic CNS rebleeding&bull;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deaths",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The dosage of subcutaneous heparin in all three studies was 5000 IU three times daily. The day 10 versus day 4 comparison was a randomized study, while the day 2 study used the day 4 and day 10 data as the historical controls in a subsequent case series by the same investigators.",
"     <br>",
"      &bull; The time from ICH onset to CNS rebleeding was not reported.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dickman, U, et al. Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage. Klin Wochenschr 1988; 66:1182 and Boeer, A, et al. Early heparin therapy in patients with intracerebral hemorrhage. J Neurol Neurosurg Psych 1991; 54:466.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19563=[""].join("\n");
var outline_f19_6_19563=null;
var title_f19_6_19564="ACC AHA preoperative ECG";
var content_f19_6_19564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Preoperative 12-lead rest electrocardiogram (ECG) prior to noncardiac surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that a preoperative rest ECG should be obtained in the following setting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Patients with a least one clinical risk factor who require vascular surgical procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Patients with atherosclerotic cardiovascular disease scheduled for intermediate-risk procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The evidence or opinion is in favor of usefulness of a preoperative rest ECG in the following setting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Patients with no clinical risk factors who require vascular surgical procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The evidence or opinion is less well established for the usefulness of a preoperative rest ECG in the following settings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Patients with at least one clinical risk factor scheduled to undergo intermediate-risk procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that preoperative rest and postoperative ECGs are not useful in the following setting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Asymptomatic patients who are scheduled for a low-risk operative procedures.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery.",
"     <br>",
"      ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.",
"      <br>",
"       J Am Coll Cardiol. 2007 Oct 23;50(17):e159-241.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19564=[""].join("\n");
var outline_f19_6_19564=null;
var title_f19_6_19565="Clinical signs symptoms HAT";
var content_f19_6_19565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical signs and symptoms of HAT in travelers and immigrants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"17%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Travelers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immigrants",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Fisher test p-value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <p>",
"         T.b. rhodesiense",
"        </p>",
"        <p>",
"         <span class=\"centered\">",
"          n = 42",
"         </span>",
"        </p>",
"        %",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         T.b. gambiense",
"        </p>",
"        <p>",
"         n = 14",
"        </p>",
"        %",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         T.b. gambiense",
"        </p>",
"        <p>",
"         n = 14",
"        </p>",
"        %",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Personality change",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        14.3",
"       </td>",
"       <td class=\"centered\">",
"        0.075",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hallucinations",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        4.8",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        21.4",
"       </td>",
"       <td class=\"centered\">",
"        0.102",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Depression",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        21.4",
"       </td>",
"       <td class=\"centered\">",
"        0.013",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tremor",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        4.9",
"       </td>",
"       <td class=\"centered\">",
"        14.3",
"       </td>",
"       <td class=\"centered\">",
"        21.4",
"       </td>",
"       <td class=\"centered\">",
"        0.131",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Abnormal reflexes",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        7.7",
"       </td>",
"       <td class=\"centered\">",
"        23.1",
"       </td>",
"       <td class=\"centered\">",
"        0.012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Reduced level of consciousness",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        42.9",
"       </td>",
"       <td class=\"centered\">",
"        0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Extrapyramidal symptoms",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        14.3",
"       </td>",
"       <td class=\"centered\">",
"        0.202",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sensory deficit",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        7.7",
"       </td>",
"       <td class=\"centered\">",
"        14.3",
"       </td>",
"       <td class=\"centered\">",
"        0.064",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Motor deficit",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        0*",
"       </td>",
"       <td class=\"centered\">",
"        15.4*",
"       </td>",
"       <td class=\"centered\">",
"        64.3",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         0.001",
"        </p>",
"        0.0115*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Daytime somnolence",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        4.8",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        46.2",
"       </td>",
"       <td class=\"centered\">",
"        0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nighttime insomnia",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        7.1",
"       </td>",
"       <td class=\"centered\">",
"        21.4",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0.168",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Daytime somnolence and nighttime insomnia",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        2.6",
"       </td>",
"       <td class=\"centered\">",
"        7.1",
"       </td>",
"       <td class=\"centered\">",
"        23.1",
"       </td>",
"       <td class=\"centered\">",
"        0.034",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br/>",
"     * Significant difference between T.b. gambiense and T.b. rhodesiense travelers.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - Do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358. Copyright &copy; 2011 Public Library of Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19565=[""].join("\n");
var outline_f19_6_19565=null;
var title_f19_6_19566="Proximal tubule transport II";
var content_f19_6_19566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathways of proximal tubule solute reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 335px; background-image: url(data:image/gif;base64,R0lGODlhcgFPAdUAAP///xERESIiIjMzMwAAAANOokRERO7u7lVVVSMfIHd3d93d3YGn0ZmZmYiIiGZmZszMzMHT6EJ6uaqqqru7u1pXWJGPkMnIyBNZqNHe7qG93DEtLjJvtHKcy62srGKRxeDp9CNkrrHI4lKGv0xJSj87PGhlZp+dnnZzdJGy19bW1oSBglpXV/D1+ru6uvLy8sjHx5GPj+Tk5GdlZayrq4OBgfHx8ePj49XV1Z6dnXVzc7q5uT47OzAtLQAAAAAAACH5BAAAAAAALAAAAAByAU8BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5ZhkRvb0ZRxkSGkvCxKC+EVUaEsBRHRKXyU7GTNVLEh15EgXd3dFGEQUMS+LkoN4FGM5REQwgUtyX6etMIAzK8kjmTAXgd7w+FPgQgdc7AO5AiOvwQYIIAPeUReQXYYQECSmEMNCQ4dykbgBSFBgBYGNHAC2gfQDW8WHLhAA0MBCRrUVDYCAa1gSgrxJI/5EkWzCQMOJhRBEaJoYYFyEiRHwLGxrF91SZP4QWMWrk6JENg3EaCyj72qtACAYcCvACa44fgw9DCxBTB5ISSHHR6BYAwAEDWgzwJGCIwCGEULE8zS7FwC0EQglvByaetxcvX79p12LwZ07D5mEUmZpFqzY0uatv487dvNfN13NkS4rlJ0I0ubZgW6QYkfY0B8qk5/4GkKGAttoZW4TYDCy2PH76NDS82tPuuLQc/UXGZ1wI9NamadtGCPaqbt7lh795HXbsbLbjcZPrm0Lk6X/WLx67Sv42WAACOSZbPpWBJU8HxllW3Uf+DEMeZAxA9d933sHHnX8X9gfAVfTZt/8hfm2wF1IBHDCwVFkEZVacX9xkaFYECN5HWRH8AYBBCBWpFdNIkjlXIDnycIMUda35VKQQGGCgQQQpLDmhgQWIkMGKcXGXolpUtvjhhjjGuCUcIrbADQcjvLeZkkIgGIJAGWrwTXkgSlLXEDVmkFYIxGTAmGwyIfYclMR9RuSMRGRQplki8KOhCJtlpCab4px5zKNw7uhPpbpkqummnHbq6aeghirqp9eMGlMzSzDDThaq8qTNJtAQ52CsjiiaaY1GxKaErlrEhismMmm4oCL8BBvTbTONMIJQDkLU0EoIzSRVJ26eBYKxwX612wjAwJRQbMwQNVUESBGh20XJDVX/1IBfHgICNOtCIwG0MkUwbwvHCrtXThd1gK9MIKTQETH3PLQHhZN9hUFaC28GAggLM5CkbIx1Aw+s6jSjjzxfQTZxbGTFNkIHJhagEF34cdNBBxhcRlpHiP06SAtJvhXNWSw7xs0HCJL0J5CVQSbQB4ltFsFyIx6jB8IcxxwNWSLBxY07iCGoDCf8bbxXbFaDLFZs90hw4kJFFEc0RMUJPY6vcQoi0jHwwCjYXvqkNRnC0nETDTf4yiZCX30wvbXTA34FV4T3IMarJlm31rR7VENOFsQcSPdeVxpWCCE+bCPCa21F2a313YAi2IGCRYJAYnd88FPmyJuxi5pYxXGQ/2gHMEPeyYsgvM7y4Ckw2rJIJZ5Iljgj2Hu5EUmK8LeNSjLZp1VtB1J7BBqM8JoISyXG5EikA53YkHsfyY2OrYOVwVLoyf40Yn93w0HiunPyFZbs262wWcCISWKZkQOQOtJSFswR51DRMFQ3QiCCziEifuNowZ261xh/4Otnk9HTpcpHBDepx1QgDMSwrIAgpYXwhH0YYRWS1DcUuvCFMIyhDGdIwxra8IZqOAAOd2gIHfLwh0AMohBl2AAEIOAACnjAApLgAAUIwQFDTMIBDDABADxgAE48wgQCIIQBUCCKRWiAAAQQgAcIQAECGIAQDrAACCzgiwEgAAAcIAAwHv9hjAAYQAAaQIQDUOAAEIDjEhEARgc8QAEKaIAPEWAALuJRAQEgox6FwMUHPACMExjAGNOox0gGIACTBEAjyYiAOkbSiGBkpAFW+UUFDAABjqyjGNEIAQHoMI4GgAAYD9CAXjaAAmSEJAEAyUUrCqCUAKgjJMuIQx82AQFeFAAFBnDJWQpgi0s0AAEuacciNBKNAvhlHQEAy0YCIAAHOMAnddnNIUAAAVAcADWfKAAz0lGXE3iAM9sJgAXIc5UDWKUQzFjKWi7xAYTk5xB8uIAlKvShbUhnOhvaUAhYdAIT+GIUISDPgP5zlSANKUA72tEzDrEBn0ypSlf6yU1usqT/6IwiJDXp0pra9KaRHCIdsyAAhwrxAeh0Y0OngEwhipGn7BQiGrFwxZOO8wo9jeJOrwBNnT7VClG1KlPVaNSrVkEASS1FOucwVSs0tas81agQy1oFV4JCom2kqEXnalEK2JUCEMgoXS26AIn6Va51xegEfOmAwhZWAU00LCwpIFi88jWu+0SCNKN41CW4lKQkbSlJb8pZzHr2s5wN7WdpalOakjSkowUtaTnJydRiNrQubSlsW7tZAsizpixlwmSHOAGvGqGWvmyAA4TbS8SS8QFNRGxhfTlYjDr2sX39K0Wn29eG+jUWtWQCV5VwTcr6tgjZVYICDDBEYGpXt1V0/+oSwpuEBxjApz80rxIOsN0kdJe39T3CAr5LBPfCl4fsTUJ+78hH/K6Xv0NgZGR3GGAkDNgI4aTsg4nQYCMgdKPnXcKCf3iA9CZhv0toI0SLMOERzxfBJj5CiVO8xj6imMVEWDGMiQDiGS9Bxjbu54ttjGMIbFihNc6xg5mAgP/+cALkVUKQIUpSbg45CUUE5QM8zGAFlHICYS0CfaVoZSMmlIdGtGSBn4wEV4LSAGO+gog15UpJQhEJW0bCAq64yi8HopeiwHGSpbDEsQ6BAgZQo4+jIGIITBkOExWCWgEA6AFUcdFO0CEEEtkEQw/gx2vEsR4gYAD3XpPTTgamAP8cUEsZUyCSC+i0nRGx41VreAALQAABYk1IHSJRk3PebRKAqUZYvjKSe2bDFZcqSiI0QJNQzOUSepvkNOYRlE+AtBHiTIhZahOdqExwQg1w1esKAQJ0hOQ5F3GAHRNajSgNJyEP+W0+mjGpJM0iAOirxkCvkgABkDcbkI1vTltR2e4VQoQpOcYAfHm/dXSAbQGAb1dXYYqGEGMTP0kAKweUi2wUQlHf6dFgf5Lb59T3IcwNBX8CoAHaJAACMsnMIZjRofQNNBYXKk8zfvIAdCxmGwIdZYMfAJarHvgce0nqGDs60HUst86xYPJC0LGJhCTAGbm9dHKOM5ObDHYtcxr/AGkTotxdgPixGY4AMR6TCLRMMCIVoNb9erGRXWd0sNcgTwcg4AH4BgAk5y70SJJxz/SG5ToZrWknNL3ao3YAeQWg8mNW3YxDeKNQI/9Oc5K8D2DnAsQdoMZXOgDYxs5qEkrdTyO+Urhv4DbnRUmAdOdX6A0QrE+3KE3B93a8W+CoIT4/XnS/UupVh+UShi3KC/dwoZePtBon8OYlOoACaRY3E/C6Rl46ANNn0CQFsuhjRL55CHtkQl/DaGQrTNMQmXSyElCufk0kfwtULsRZ4fzmI8ZB9z0sv7ahsGBefp0I7wcFBkABjCRKUDRePaV4TXB4eNBnS7REFPBy8/YE/9iHBfiHCMcmRgPAexAQSQ8wTXOnYjqUSYpkANlmCAH4BFw0SZO1AG4lfUsga3pgAA6wXz6mRuOVb3lUgf00c2HAgIYAS7QXUDp0dwO1Y7OmdxUHSTBYCCnoBFzUSEW0UHx0akRggkY0ZpxWdXUQALpUccjkgrZ0Tj7VWqHGeCLXBUBYCGi0AHEkb0Oldzonc84Gfg+Yb2R0ag4HCE/YBFGIb1zYgUYnT1kETbLGg21QTPj2YDH1RMnlYQgATGmoeYXHB2akTp90BMQmSiBlZwFwh5znhQHwfYRQiVKwgp/4iUVghQlmSWw3UIE2a4i4BorIeFy4dAUXAHuWRlI3Bv+mqAdmRAFSRwC92F9PdViIRQQE8GhlBEnCdwi/CAWzRkYLIHVptkUa1mFcSAeKCAATsIxFsI1GsF+k6AWZhwiwhESKxG5EUFTixUcuyEdI9H9DEI0qqEhJsImGIEei9EUDkGYM5wRe1wV9WAd0NJAnF1CeoEazGAUZtX5ZRghxx11ycI6IMGiosGUNmWIF2U4dyU8faUf2CFEWKWQkZpJSNJIKpZIKRW0oGWMveQQuGZN5RJNGwJLthJPtNJMxqZPdtIYv6ZN2BJQoKZRgRJQmaZQbpZRCFIIxyVEbiUKFpQVOuUNYlgX+FJWaEmhzdklIpG/yBJBUUJUuREYZVV//3FZPTHdpC9gppXRMxChKCJBXAreBWYBjCDeJmiJr2DZv7ERpa9kE5RaJWqkKKEVFjWRIigdWcCZSjtmJYWZEBodQd2dJlglSxCh1ZIkLYkQAhkaA7wUAGEkEE7B2hrVcREd0hgVUiHRIXuZldZZykXR9utBbe7RMjgZLYvltY+RanJSZUkdGcUSMLEVxxMmUpGBIxGlmuzlvaYlbKwWc0pmZZHRTwKlEtblFVqZwjaeDcGZr1hVXcRVJtlWDpNlJ3rlGkhQqTZRM3VmOUNBbgEic0blwRqCXtjBFbMdIuoRcY4Sf2uWFTGBOKMSVzPZJ7RdpspaZwzmfDlpxozIB/0sUSD7lZ1IgnABKBC1VmDQkm8AZR8MJosCZoT80ilFwasgZKjqEd/gGiBSXUsTZosPJTyg1BZ+3k9Uooy4KozHao2OoolpgRhO2clr0AB24h0DElyHaojrqog5KorRgoVpgcMx3ct/XSFyFmqI0dfcVRW7IpCLKpPTJUvZpVYOli8koBJmURb15SdDkRAZnR4w3n8Y5nXXqoGAkAOTVmQFQmmc3AbZmi5EncCFpKiB6qDD6ojIapnHEoSc0akNHdkD1ZW+pR/EnX1HEoGO6qSrloHEEnzzkReRkAIO5ngBIU2FVkkEkog3KoIlKpm8YRT5ZqKPSpKxqnNG5pEh6Q/8+maK38GM7KqbCeqcxuqs2NABhBUXQxFpz+WG06inO5KrFGaKHCqYQOgeOOgn/uFBcRID15HdcNVQYyVY8FK3TKZ0N2qmKGn9vkK2SUIfkBG1oZGYvdUaapGx4BEasCqZ1Oq0zKlZ3UEpfZHfcNmnhpEkn15u9KQSzJJIPKqatiqjG2WJBtF/khQAK0FuHNGoI+3l6mkSQirB29Hk7GqYfGqPGOU7uOircBmtCAHNNcHbd1AAlq65jqq7690NN+ATP2E7SWrPFSYygKkSf1JxHgFJxWgULYLSgcmpOyqn1aY8ZF0N6BKXnVIkixlADta0otEV0+rWdKnU5q199BU3/CGkqPStFBNoEYsRFOoisyaSLLySMN/uidcqW4kdGz1ZL9TS2umBGogeAn+RoYXRte7RhgNRHiNSnoFRVejeAozJPRsCdN8ukcPudFqq3k1SloVJK1LlaLgWcmxSiqvSYACVt5EWMz7oK4EZGUleZrohIA3Cu1ylSAWVvMidvepRzIKRHmflKr2mZiPSaukiZtntaHgVp85hSvmoKSMagsKWuslVTngVS35eHegtCP/dJ7EpmVKBHo1ZG2pSgofIATEtzVqB0oiSONrSZTUCwk/ZF5vtDSLmABYh7QUSqNrlQ7mtj/WtjELe/xSbAzknA/ztjAWyTU7SydkRfDAyo/0G0wATMk1MAaENbQwm8vxQsBZBEvrxKwPOmk+pUjEB0wDOmk5QrRM37QzqZcvwIRCscqlnAeec7QzG8Qz55bN37wSDskzQcwTeMQz7MtUC0ukM0xDW8UAwcC0YsRCH5dEzgQ0vMxCCcTFmARkksKu/UvU0cRCGJRjtcoJlYBF1cxDPcpTQkoABYxSEpRmfrKQuww3q0aGX8Q0/MmKHiRVsWikOrR0lVxzzUxoHrKbO2VLE2yFeoxoC8Q4Lst7mwiBqFczeWieyLkoI8xanQohcsk11XySYpyLVaSy/sBHDHxlmAjSpKAIzVelEwu2H8yafsyR3apwKsqlOATUc8xv80ucEO2YhDNJE0GZKnhsm24LICRstUQMyf4pMdqMy0UMrHnMVaJpIoqcYOhswoacI5ac13hM1CFsSz4K70BczdLM3tpM2VdpWWgESWpHdO1AAf2ACIFJGRhWQmyEtG9MYBerZj5Mw2PAVu2FOhtL6MJMuKAEqfl1L+RACFdUj/1WkaanAJnW+w1JGdpAT2981UEEkcVUwQsHDqRAfbBwbFpADAF4rdi1Cn5EMqNwTbJHAGzQThV8Uj+UmC90SsfE4RmQWA5EZuxEZjJcUTqEM0e0bEzI9FrYt5eAQFfUws/WUv/WycWwWWStMbfUZkZHdxpEZuuNNXkEmaBLqxFbT/xOnBG61Ph8ppOa1idtZwSGSNQPWtm9wEVU3ANV1Hk1RLZoRkixyfP9oF7lWAuHZlu/ZfrhSJesdIVYRzK4tvr5xjI2lEB+BernRJllRkl9DTFrhgKEdFWKBJukyTPsyOMExJjw1j4ExDXEVG5vxQqV0KfX2SMD3XKfbapBDbMDkErB2TuA3bavB6oQ3ZL9TbXXQEM63RLmTbNXmTiMxiyi0KxL3c93naKzncahDdMvTccIYJ0Y3dVGvdxuZR7uYF3g1D2g0KV+WMxxZ1VvsE5Q3eKHRVY8xYSEvd7m3KZamh9QVNZcpT+B3fET0EJDi7Xj0F753fCP5EoDS85KVw/+hMkSB84J3gW/6s2//9qNd94SGk3BKO4cl93RUeyC/E4Y6cvjjU4ZtA4mAgUdud4NpbTvosRRda4lPA4jycnwuV43I2nDHe4lDw1/uLtxtOwmbQ3EEZ4qggjGYNBsYswEIeQtH95DZ53p9grF8g5TT54LrQ41yA5TGp5a5N4zAG5rGglVJ6l2IOQ+2ZBWT+Cq4EawJVVbdbRya4gXZHpFtwuTM0WGpKBI1G203Q5q6ASCqXiVndp1tUUEDFRmlO1wVeBIiE5J7AnXnURq00RlZO1xXqZ9d1SvgIC9u7TMuUd3Nkn8ftrDjlryULWwzqg5pCgBVnpJq02AvGea71T/+3JU+g1Foyt1mzm5loFguf10lta5/fmGSjaKRK9phh5oro2qoY25qXjVC/S4OcMgGCt4yNhKRXRFvVS7uie1lhzaAfCAvwFGiGDnzDy9GNpLFW8KFkTeRDwHOfUkSBVOhySwUoBbQ8KqD7ZN+n0GlVhEq4h1AZa0WWpEsya+D8TqaAvilX5G6ipr9TULfTKnUA/6s09m3wRAVz6q/12d47JJsgH7Yx3SlLSwXSWvK4qlAsyvJk2ugzpHAwH7QKZfEwj2+tHUMLquogj2+SzmY1f/FUHgsSO/TGueSM3PAsT+pDJExIT6Yo3gq/HvXR+eg2ZItWr65yWrOLyvRxlGb/QT8LWr/1E6uvYN/0mT5DR7/1o0y0YO/1nerlOGT2ZGpHOI/0Ujf2tpD3em9HbR/1/Q1Ega/3b7+qaV/yLT1EZW/2Tv/Lif/zIg9Dhmv3j6/Cfp/zXB5DJh35ZD31rOC1rzr0cZlKmf/zquiwimq3DU+cQ1n4TT/5NFS3wXrx3Jypnp+oCkWteq/0PMT7OX+t7USyJdv6pS9D4yXNThv5xLj2P/TyTU8Agi7sZxdw9aiLWG8Ep+/6usBtMgdNY5+uF0+MCfp8n/KNy2h39n5yiD25sddYdmVRdATv01l2qrlcw0mDMs8JcQoEhwli0FhAJoCJA+BoAIQQACUJsF6x/1ktYCEgfMFhgoECgRzPi0Bg8Dhs4XH5nF633/HzxWOtaCAEEOQOBAoND9fWxMQSGw3DBpjyJikrLe0CKAAaFAwG2hwEFIgePAcMDB4AA+QaBg5hDRUXv9g+bwU+wwyqLn1/gYOv9hwIAhQmAgzmFByaHaChG6YbJijKIAye3rAOvI8o1IwfjITNz4OPAQwCiAJDRR1eHQIE1nIHWj9RDRD8/1UhUKBqoLIHBwP+U1hLlBR0DyE+DOXAAIFC9c4N0FTHX0SPH+nYc6XM0IB67QA1CKSgUCR0AxyClDnz4YIJ3IQ0iBlMI02fP+Vk68dJW78HFD6tQ0BBVYNQ+TLuBP86lWpVLDCtZtU6FetWr18fdgU7lqwvsWXRpp1zVm3bOPXwQZWjLItUs3bd5i3LVm9fNl4KPYHgZwqTJRAKabJJSJCDXpb49pW8dcCCyZNPsqmHoF+kzom8HANkcoCCPncvp6bMTbXbNUUPAcjMBwJcAQZYFiJS7wHq1r+BDmANHC1GAK9MBlApMJeACa9i3WZH+FJl4tdlChiOHWwuK51IpaLgj54BeZ785fJUG8H2ScK5x38owLL8y/RmyrW/3xd9/pPdg0iA/wisZMACtzpQiwZ6w2OITdqZREEEKZwjgAArnImCTKywSYkFDrAMgo0mqI8La7h4YgEKDgAEgWr/MNxiwgxpxIKVGn9CygsA7IFLmcygs8eKVUZzgI9c2gngAUnqmBFHGm98ciaVKvIEH8T4CJINdqwo5ccu16DSHkHscFJKCqM886M2ECPApFw2ROAvfEh640cECEBggoouEuWVO8xUk8A0BYWoJzlN0TMQfAKBYID2rDAATnYOeEAAV3Dz4zELC82Q0E4L/BTU/UQdldSNTOWPw1QJFABVVuVzFdb/nJvVPgHwspW4WnXlTtZe4+MV2F1NHHbXV41Vzb9kd82VWb0CKPbZ1Jad9rILrW2t2mz9kpbbth6QAttv/XKWXLDwk83bc4tbl92tFgjDCuWuuWZEKiaYoJp8//O9hhqnnHDGGYQI9ichhQ4aSIGFGXZmYWgWToifU265xZSKPeFH434mRqVi5KJrrqUggwxZlkZQTtnkkFNew913tarlintWrrlPmm1eueWdcS7p459xyRmWjzfmTKF+jEYaFc6QNpighBt+JhqBIY6Y4YepccyaMmAmC7EA8rxigoMQQMhphco2m+CHsaZGX7f/3ZdfKrAx44wQWXvDm26g+MYbv/F+uevBy9yW8MOH7cJcxBkHFbFCGo/c1kJilNzyJwkZ9/LNBaWc88/V1A700Ws0hHRWK3+2EMFPlzJ1ZpVrXXZa15jddvkOCGDT23lXtvbegVdNzieCL94SGP9gsAQHFmi4g4UaADjKeHOQR96GS55HZ/nm/0sgAUtuiCF5OxJgYXp0vPe+h/EpKR8OFr6nBIYEYiDQeyxi4D5/AGCIYYcZZmCDGDAPAOFLHg38B0Ac8G8GLGBBDqzgvvOZ4341oF8BdeDAGlwPBxmcQfNsUAMW6GCBAHAfDBr4QP7xgH7JQ+HzrofAG+TgBi9U4fzq1734RbACPASABRKwARIEkQQbSIAMLpAACwCgAgkowRBL8EMUWKCJHjBhDycoDO9ZgAQlkAEALlABC6AgASiQQQJIMEYTAKCIXNzAFxPQwzFSMQEe8IARK+ABFyTABCvgIxODmIALzLGKSVz/og6xEEcfAvECV/yhIA0JSCsMEQAvOIEJhrhERWYxGN6rQAmUaAUPoKCJFVCBE1dwgheccgUA2OMJHGlJTIayiVYwgRItAEpAvsAKssxkJBF5hU0qkpGOZGQkaynJIp7gBKHcJCd/cT8Tfs+PK0hiD11QASOSIJKRVOQym7nEZDbRAuUU5w7BqURg8meL5QSAEVdARjkK0piQpGX8aunEC/hRk1iEpi+8d4FmRrGJLvBAHC+AAhdcYAMbeGcJLnBLFThSn/wEpAtU0EwTXMAFKJBkBCHKz3XuJ333u+MG/DjPRhLTnue0Qi0PGkdn+vOfliipKQGgAjzGUQZDRONE/1UARSs6MqbkdKURYZlL760xmQAoqjpDWVOpTpWqVbXqVbGaVWZ5AKdaLcsKaMq5YnqVLE01lgU8QEUPqMAEJuClUytQAVg61QLZXMELSDlRIF7SBBMdpAo8cAEZkLICd6WrC9o6UbjKVasyqGte7dpLKprABVZAq1rZ6taLVgAFvEyrDE6ARBPEda5oPQFnefmCyVa2QN4rohOH6NFq3hKWTSwBKDdg20eKsaGPNKIFwjjGMgLyiU4EwGwTMNerJlGmG7htHdm4AS4mYKKuNWJxPdpEFPiRqYEc5BSrOM0uDreNQ1Rs91TqSOeWU5G1ROb3iunHQSaAtU4lZXvjR/zJ9QIxrFR9LxiVeEoxkrGfj1xpD5NJySa+1ZczrWQcBSzcQ6LXwBQtgTmt6N57VpiRY63mNT+azwuXc6jL3bAhr2nOA1cYvy/9XlPTWeArpricjbRfehV5S+CmVZL/3asLejvWgh4Uwfj8no4vwGOs/jeSDQ3sCazI0hU3UaB/bGpFHazeDTy5xOzEcQ/xakTp9njDQLyuXumZ050W2cWVRIGYJ2xVJoeSrd4rQWWl7Mgm4pGXTX2qjBVZZyfWl6yFNvShEZ1oRS+a0Y129KMhHWlJT5rSlbb0pTGdaU1vmtOd9vSnQR1qUY+a1KU29alRnWpVr5rVrZ5eEAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the chemical and electrical gradients and some of the carrier-mediated mechanisms involved in proximal tubular solute transport. The low cell Na+ concentration that is maintained by the Na+-K+-ATPase pump in the basolateral membrane permits secondary active transport in which passive Na+ entry into the cell is coupled by specific cotransporters to the uphill reabsorption of glucose, phosphate, and amino acids, or to the secretion of H+. Units are meq/L; CA represents carbonic anhydrase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19566=[""].join("\n");
var outline_f19_6_19566=null;
var title_f19_6_19567="Thrombocytopenia";
var content_f19_6_19567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Thrombocytopenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG reflecting thrombocytopenia.The red line is a normal tracing.",
"    <br>",
"     This study shows a normal ACT, R time, K time, and LY30; low alpha angle, MA, and G, reflecting platelet hypocoagulability.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_6_19567=[""].join("\n");
var outline_f19_6_19567=null;
